Document:

EX-4.2

 Exhibit 4.2 

REPARE THERAPEUTICS INC. 
  

 
  

AMENDED AND RESTATED 

REGISTRATION RIGHTS AGREEMENT 
  

 
  

September 3, 2019 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 ARTICLE 1 INTERPRETATION
	  	 	1	 
	 1.1
	 	Construction	  	 	1	 
	 1.2
	 	Severability	  	 	2	 
	 1.3
	 	Governing Laws	  	 	3	 
		
	 ARTICLE 2 CERTAIN DEFINITIONS
	  	 	3	 
	 2.1
	 	Definitions	  	 	3	 
		
	 ARTICLE 3 REGISTRATIONS
	  	 	8	 
	 3.1
	 	Demand Registrations	  	 	8	 
	 3.2
	 	Short Form Registrations	  	 	12	 
	 3.3
	 	Piggy-Back Registrations	  	 	13	 
	 3.4
	 	Transfer of Registration Rights	  	 	16	 
	 3.5
	 	Co-operation	  	 	16	 
	 3.6
	 	Termination of Registration Rights	  	 	17	 
	 3.7
	 	Limitations on Subsequent Registration Rights.	  	 	17	 
		
	 ARTICLE 4 ADDITIONAL PROVISIONS FOR REGISTRATIONS
	  	 	17	 
	 4.1
	 	Rule 144 Reporting and Form S-3, Form F-3 and Form F-10 Requirements	  	 	17	 
	 4.2
	 	NI 44-101 and NI 51-102 Requirements	  	 	18	 
		
	 ARTICLE 5 REGISTRATION PROCEDURES AND EXPENSES
	  	 	18	 
	 5.1
	 	Registration Procedures	  	 	18	 
	 5.2
	 	Expenses of Registration	  	 	22	 
		
	 ARTICLE 6 INDEMNIFICATION
	  	 	22	 
	 6.1
	 	Indemnification Provided by the Corporation in Favour of the Holders	  	 	22	 
	 6.2
	 	Indemnification Provided by the Holders in Favour of the Corporation	  	 	23	 
	 6.3
	 	Indemnification Procedure	  	 	24	 
		
	 ARTICLE 7 GENERAL PROVISIONS
	  	 	25	 
	 7.1
	 	Notices	  	 	25	 
	 7.2
	 	Enurement	  	 	26	 
	 7.3
	 	Counterparts	  	 	26	 
	 7.4
	 	Assignment	  	 	26	 
	 7.5
	 	Entire Agreement	  	 	26	 
	 7.6
	 	Amendments, Modifications, etc.	  	 	26	 
	 7.7
	 	Additional Parties	  	 	27	 
	 7.8
	 	Further Assurances	  	 	27	 
	 7.9
	 	Specific Performance	  	 	27	 

  
 i 

 AMENDED AND RESTATED 

REGISTRATION RIGHTS AGREEMENT 
 THIS
AGREEMENT made as of the 3rd day of September, 2019. 
 AMONG: 

REPARE THERAPEUTICS INC., a corporation incorporated under the Canada Business Corporations Act (the
“Corporation”) 
 -and - 

Each of the Persons listed on Schedule A (the “Class A Investors”) and Schedule B (the
“Class B Investors”) and any Person who becomes a party pursuant to Section 7.7 (collectively, the “Investors” and individually, an “Investor”) 

WHEREAS the Class A Investors and the Corporation are parties to a registration rights agreement dated June 22, 2017 (the
“Original Registration Rights Agreement”); 
 WHEREAS the Class B Investors have agreed to purchase
Class B Preferred Shares as set out and pursuant to a Class B Share subscription agreement dated August 27, 2019 (the “Class B Share Subscription Agreement”); 

WHEREAS as an inducement to the Class B Investors to complete the transactions contemplated by the Class B Share Subscription
Agreement, the Corporation and the Class A Investors have agreed to amend and restate the Original Registration Rights Agreement as herein provided for; 

AND WHEREAS the parties hereto desire to amend and restate the Original Registration Rights Agreement and to enter into this Agreement,

 NOW THEREFORE IN CONSIDERATION of the mutual covenants and agreements contained in this Agreement and for other good and valuable
consideration (the receipt and sufficiency of which are acknowledged), the parties hereto agree as follows: 
 ARTICLE 1 

INTERPRETATION 
  

	1.1	 Construction 

In this Agreement, except as otherwise expressly provided: 
  

	 	(a)	 words denoting the singular only shall include the plural and vice versa and words denoting any gender shall
include all genders; 

	 	(b)	 words importing persons shall include individuals, partnerships, associations, joint ventures, syndicates, sole
proprietorships, trusts, unincorporated organizations, limited liability companies, corporations, trustees, executors, administrators or other legal personal regulatory bodies and agencies, governments or governmental agencies, authorities and
entities however designated or constituted, and unless the context otherwise requires, any reference in this Agreement to a person shall include, and be deemed to be a reference also to, any successor or assign of such person; 

 

	 	(c)	 except as otherwise provided, all amounts in this Agreement are stated and shall be paid in the currency of the
United States of America; 

  

	 	(d)	 the division of this Agreement into Articles and Sections and the insertion of headings are for convenience of
reference only and shall not affect the construction or interpretation of this Agreement. Unless the subject matter or context requires otherwise, references to Articles or Sections are to Articles and Sections of this Agreement;

  

	 	(e)	 references to “herein”, “hereby”, “hereunder”, “hereof” and similar
expressions are references to this Agreement and not to any particular Article or Section of this Agreement; 

  

	 	(f)	 the word “including” shall mean “including without limitation” and “includes”
shall mean “includes without limitation”; 

  

	 	(g)	 the expressions “the aggregate”, “the total”, “the sum”, “collectively”
and expressions of similar meaning shall mean “the aggregate (or total or sum) without duplication”; 

  

	 	(h)	 in the computation of periods of time, unless otherwise expressly provided, the word “from” means
“from and including” and the words “to” and “until” mean “to but excluding”; 

  

	 	(i)	 whenever a provision of this Agreement requires an approval or consent by a party and notification of such
approval or consent is not delivered within the applicable time limit, then, unless otherwise specified, the party whose consent or approval is required shall be conclusively deemed to have withheld its consent or approval; and

  

	 	(j)	 whenever any payment is to be made or action to be taken under this Agreement is required to be made or taken
on a day other than a Business Day, then such payment shall be made or action shall be taken on or before the requisite time on the next Business Day immediately following. 

 

	1.2	 Severability 

If any provision of this Agreement is, or becomes, illegal, invalid or unenforceable, such provision shall be severed from this Agreement and
be ineffective to the extent of such illegality, invalidity or unenforceability. The remaining provisions hereof shall be unaffected by such provision and shall continue to be valid and enforceable. 

  
 2 

	1.3	 Governing Laws 

 

	 	(a)	 This Agreement shall be governed by, and interpreted in accordance with, the Laws of the Province of Ontario
and the federal Laws of Canada applicable therein. 

  

	 	(a)	 The parties hereby irrevocably attorn and submit to the non-exclusive
jurisdiction of the courts of the Province of Ontario with respect to any matter arising under or related to this Agreement. 

ARTICLE 2 
 CERTAIN
DEFINITIONS 
  

	2.1	 Definitions 

As used in this Agreement, the following terms shall have the following respective meanings: 

“Additional Parties” has the meaning given to that term in Section 7.7. 

“Affiliate” means, with respect to any Person, any other Person that directly, or indirectly through one or more
intermediaries, controls, is controlled by or is under common control with the specified Person, or any venture capital fund, investment fund and separate account now or hereafter existing that is controlled by one or more general partners or
managing members of, or shares the same management company with, such Person. As used in this definition, “control”, “controlled by” and “under common control with” means possession, directly or indirectly, of power to
direct or cause the direction of management or policies of such Person (whether through ownership of securities or other partnership or ownership interests, as trustee, personal representative or executive or by contract, credit agreement or
otherwise), provided that in any event, any Person which owns directly, indirectly or beneficially 50% or more of the securities having voting power for the election of directors or other governing body of a corporation or 50% or more of the
partnership interests or other ownership interests of any other Person will be deemed to control such Person. 
 “As-Converted Basis” means, for the purposes of this Agreement, that if a calculation of a number of securities is to be made on an “as-converted
basis’’, the number of securities is determined as the number of Common Shares that would be held by the applicable Holder if all securities held by such Holder that are, directly or indirectly, exercisable or exchangeable for or
convertible into Common Shares are so exercised, exchanged or converted. 
 “Articles of Incorporation” means the articles
of incorporation of the Corporation, as amended and restated from time to time. 
 “Business Day” means any day on which
banks are generally open for business, other than a Saturday, a Sunday or a statutory holiday in the Provinces of Quebec and Ontario or the State of New York. 

“Canadian Prospectus” means a preliminary prospectus and a final prospectus (including the short forms thereof) prepared in
accordance with applicable Canadian Securities Laws for the purposes of qualifying securities for distribution or distribution to the public, as the case may be, in any province or territory of Canada, including all amendments and supplements
thereto. 

  
 3 

 “Canadian Securities Laws” means statutes and regulations applicable to the
trading of securities in any province or territory of Canada including applicable rules, instruments, rulings, policy statements, blanket rulings, orders, communiqués and interpretation notes issued thereunder or in relation thereto,
promulgated by the Commissions in Canada, as the same may hereinafter be amended from time to time or replaced. 

“Class A Investors” has the meaning given to that term in the preamble. 

“Class A Preferred Shares” means the Class A convertible preferred shares in the capital of the
Corporation and any other securities issued or issuable thereon or in respect thereof (whether by way of a share dividend or share split or in exchange for or upon conversion of such shares or otherwise in connection with a combination of shares,
distribution, recapitalization, merger, consolidation or other corporate reorganization), and for greater certainty, a reference to Class A Preferred Shares includes Common Shares issued on conversion of such Class A Preferred Shares. 

“Class B Investors” has the meaning given to that term in the preamble. 

“Class B Preferred Shares” means the Class B convertible preferred shares in the capital of the
Corporation and any other securities issued or issuable thereon or in respect thereof (whether by way of a share dividend or share split or in exchange for or upon conversion of such shares or otherwise in connection with a combination of shares,
distribution, recapitalization, merger, consolidation or other corporate reorganization), and for greater certainty, a reference to Class B Preferred Shares includes Common Shares issued on conversion of such Class B Preferred Shares. 

“Class B Share Subscription Agreement” has the meaning given to that term in the recitals. 

“Common Shares” means the Common Shares in the capital of the Corporation and any other securities issued or issuable thereon
or in respect thereof (whether by way of a share dividend or share split or in exchange for or upon conversion of such shares or otherwise in connection with a combination of shares, distribution, recapitalization, merger, consolidation or other
corporate reorganization). 
 “Commissions” means (i) the SEC, and (ii) any securities commission or securities
regulatory authority in each applicable province and territory of Canada, or, in each case, any successor regulatory authorities having similar powers in the United States or Canada, as the case may be. 

“Corporation” has the meaning given to that term in the preamble and includes the Corporation’s successors by merger,
amalgamation, acquisition, reorganization or otherwise. 
 “Delay Certificate” has the meaning given to that term in
Section 3.1(c). 
 “Demand Registration” has the meaning given to that term in Section 3.1(a). 

  
 4 

 “Final Prospectus” has the meaning given to that term in Section 6.1.

 “Holder” means: 
  

	 	(i)	 each of the Persons listed on Schedule A or Schedule B; 

 

	 	(ii)	 any other permitted person to whom the rights under this Agreement have been transferred by any of them (or
their respective successors or permitted assigns) in accordance with Section 3.4; and 

  

	 	(iii)	 any Person that becomes a party to this Agreement in accordance with Section 7.7. 

“Holder Indemnified Parties” has the meaning given to that term in Section 6.1. 

“Indemnified Party” has the meaning given to that term in Section 6.3(a). 

“Indemnifying Party” has the meaning given to that term in Section 6.3(a). 

“Initial Offering” means the initial public offering of securities of the Corporation in any jurisdiction. 

“Initiating Holder”, for the purposes of Section 3.1, has the meaning given to that term in Section 3.1(a), and for
the purposes of Section 3.2, has the meaning given to that term in Section 3.2(a). 
 “Investor Shares” means the
Preferred Shares and the Common Shares issuable upon conversion of the Preferred Shares. 
 “Investors” has the meaning
given to that term in the preamble. 
 “Law” means any and all laws, including all federal, state, provincial, territorial
and local statutes, codes, ordinances, guidelines, decrees, rules, regulations and municipal by-laws and all judicial, arbitral, administrative, ministerial, departmental or regulatory judgments, orders,
directives, decisions, rulings or awards or other requirements of any person binding on or affecting the person referred to in the context in which the term is used. 

“Major Investors” has the meaning given to it in Section 5.1 of the Shareholders Agreement; 

“NI 44-101” means National Instrument 44-101
of the Canadian Securities Administrators entitled “Short Form Prospectus Distributions”, and any successor policy, rule, regulation or similar instrument. 

“NI 45-102” means National Instrument 45-102
of the Canadian Securities Administrators entitled “Resale of Securities”, and any successor policy, rule, regulation or similar instrument. 

  
 5 

 “NI 51-102” means National
Instrument 51-102 of the Canadian Securities Administrators entitled “Continuous Disclosure Obligations”, and any successor policy, rule, regulation or similar instrument. 

“Notice” has the meaning given to that term in Section 7.1. 

“Original Registration Rights Agreement” has the meaning given to that term in the preamble. 

“Person” means any individual or any entity, including any partnership, limited partnership, joint venture, syndicate, sole
proprietorship, company or corporation with or without share capital, unincorporated association or trust and any trustee, executor, administrator or other legal personal representative, regulatory body or agency, government or governmental agency,
authority or entity however designated or constituted; 
 “Piggy-Back Registration” has the meaning given to that term in
Section 3.3(a)(i). 
 “Preferred Shares” means, collectively, the Class A Preferred Shares and the Class B
Preferred Shares; 
 “Register”, “registered” and “registration” refer to a registration
effected by preparing and filing a registration statement in compliance with the U.S. Securities Act, and the declaration or ordering of the effectiveness of such registration statement. In addition, unless inconsistent with the context:
(i) the term “registration” and any references to the act of registering include the qualification under Canadian Securities Laws of a Canadian Prospectus in respect of a distribution or distribution to the public, as the case may be,
of securities; (ii) the term “registered” as applied to any securities includes a distribution or distribution to the public, as the case may be, of securities so qualified; (iii) the term “registration statement”
includes a Canadian Prospectus; and (iv) any references to a registration statement having become effective, or similar references, shall include a Canadian Prospectus for which a final receipt has been obtained from the relevant Canadian
Commissions. Any registration of securities that occurs concurrently in Canada and the United States shall be counted as a single registration for the purposes of this Agreement. 

“Registrable Securities” means, with respect to any Holder, (i) the Common Shares held by such Holder, (ii) the
Common Shares or other securities of the Corporation issued or issuable to such Holder upon the conversion or exchange of such Holder’s Investor Shares or as a dividend or other distribution on such Investor Shares or with respect to, in
exchange for, or in replacement of such Preferred Shares; and (iii) any Common Shares or other securities of the Corporation issued as a dividend or other distribution on such Common Shares or other securities that are Registrable Securities
pursuant to (ii) above, or with respect to, in exchange for, or in replacement of any of the Common Shares or other securities that are Registrable Securities pursuant to the above. As to any particular Registrable Securities, such securities
shall cease to be Registrable Securities when they have been distributed to the public pursuant to a registration or sold to the public through a dealer or market maker in compliance with applicable Securities Laws. For purposes of this Agreement, a
Person shall be deemed to be the holder of Registrable Securities, and the Registrable Securities shall be deemed to be in existence, whenever such Person has the right to acquire such Registrable Securities (upon conversion or exercise or
otherwise, but disregarding any restrictions or limitations upon exercise of such right), whether or not the acquisition has actually been effected, and such Person shall be entitled to exercise the rights of a holder of Registrable Securities
hereunder. 

  
 6 

 “Registration Expenses” means all expenses incurred by the Corporation that
are associated with, or related to, the Corporation’s performance of, or compliance with, this Agreement, including, without limitation, all registration, qualification, filing, listing and Financial Industry Regulatory Authority, Inc. fees,
all fees and expenses of complying with the Securities Laws (including, without limitation, the securities or blue sky Laws of the United States), all duplicating and printing expenses, all translation fees and expenses, all fees of transfer agents
and registrars, all costs of insurance, all escrow fees and expenses, all messenger and delivery expenses, any stock exchange fees, the fees and expenses of the Corporation’s legal counsel and auditors, including the expenses of any regular or
special audits or “cold comfort” letters required by or incident to such performance and compliance, up to US$35,000 for reasonable fees and disbursements of not more than one counsel for all of the selling Holders, such counsel to be
selected by the holders of the majority of the Investor Shares included in a registration, or if no such securities are included in the applicable registration, by the holders of the majority of Registrable Securities included in the applicable
registration, in each case on an As-Converted Basis; provided however that the foregoing cap shall not apply in connection with the Initial Offering of the Corporation, and any reasonable fees and
disbursements of underwriters customarily paid by Corporations or sellers of securities; provided, however, that Registration Expenses shall not include Selling Expenses. 

“Rule 144” has the meaning given to it in Section 3.1(c); 

“SEC” means the United States Securities and Exchange Commission or any other federal agency at the time administering the
U.S. Securities Act. 
 “Securities Laws” means, collectively, the Canadian Securities Laws and the U.S. Securities Laws.

 “Selling Expenses” means underwriting fees, discounts and commissions, fees and disbursements of the selling
Holders’ counsel (other than the one counsel selected to represent all selling Holders) and any transfer taxes relating to the disposition of the Registrable Securities, each incurred in connection with a registration pursuant to Sections 3.1,
3.2 and 3.3. 
 “Shareholders Agreement” means the second amended and restated unanimous shareholders’ agreement dated
as of the date hereof and entered into among the Corporation and all of its shareholders, as amended, supplemented, restated or replaced from time to time; 

“Short Form Registration” means a registration effected using (i) Form S-3, Form
F-3 or Form F-10 (or any comparable or successor form or forms under the applicable Securities Laws), if the Initial Offering was completed in the United States, or
(ii) a short form Canadian Prospectus in the form of Form 44-101F1 pursuant to NI 44-101 (or any comparable or successor form or forms under the Canadian Securities
Laws). 

  
 7 

 “Subsidiary” or “Subsidiaries” in respect of any Holder
means any entity of which such Holder and/or any of its other Subsidiaries directly or indirectly owns at the time outstanding securities of such entity representing at least fifty percent (50%) of the voting power of such entity. 

“U.S. Exchange Act” means the Securities Exchange Act of 1934, as amended, or any similar federal statute, and the rules and
regulations of the SEC promulgated thereunder, as they each may, from time to time, be in effect. 
 “U.S. Securities Act”
means the Securities Act of 1933, as amended, or any similar federal statute and the rules and regulations of the SEC promulgated thereunder, as they each may, from time to time, be in effect. 

“U.S. Securities Laws” means all U.S. federal and state securities Laws and regulations, including, without limitation, the
U.S. Securities Act and the U.S. Exchange Act. 
 ARTICLE 3 

REGISTRATIONS 
  

	3.1	 Demand Registrations 

 

	 	(a)	 Request for Registration. Subject to the provisions set out in this Section 3.1, at any time or
from time to time after the date that is the earlier of (i) five years from the date hereof and (ii) six months after the completion of the Initial Offering, any one or more of the Holders holding at least 50.1% of the then-outstanding
Registrable Securities held by all Holders (for the purposes of this Section 3.1, collectively, if applicable, the “Initiating Holder”) may require the Corporation to file and take such other steps as may be necessary under the
Securities Laws to facilitate a public offering (including an Initial Offering) with respect to all or part of such Initiating Holder’s Registrable Securities (each such registration, a “Demand Registration”), by giving written
notice of such Demand Registration to the Corporation, which written notice shall: 

  

	 	(i)	 specify the number of Registrable Securities which the Initiating Holder intends to offer and sell;

  

	 	(ii)	 specify whether the Demand Registration is to be effected in Canada and / or the United States;

  

	 	(iii)	 express the intention of the Initiating Holder to offer or cause the offering of such number of Registrable
Securities; and 

  

	 	(iv)	 if the Registrable Securities to be offered and sold by the Initiating Holder are to be issued pursuant to the
conversion, exchange or exercise of Preferred Shares or any other securities convertible into Registrable Securities, be accompanied by appropriate notices of such conversion, exchange or exercise, as applicable, which notices may be contingent upon
the sale of that number of Registrable Securities in the Demand Registration. 

  
 8 

	 	(b)	 Response to Registration Request. Upon receipt of the written notice of the Initiating Holder pursuant
to Section 3.1(a), the Corporation shall: 

  

	 	(i)	 promptly, and in any event, within three Business Days of receipt, give written notice of the proposed Demand
Registration to the other Holders to provide the other Holders with the opportunity to participate in such registration with respect to the Registrable Securities held by such other Holders; and 

 

	 	(ii)	 as soon as practicable, but in any event within 60 days (or 120 days in the case of an Initial Offering) after
receipt of the request from the Initiating Holder, file with the applicable Commissions and use its commercially reasonable efforts to effect the registration, qualification or compliance (including, without limitation, filing post-effective
amendments, appropriate qualifications under applicable blue sky or other state securities Laws and appropriate compliance with applicable Securities Laws and any other governmental requirements or regulations) as may be so requested and as would
permit or facilitate the sale and distribution of all or that portion of the Registrable Securities as are specified in the Initiating Holder’s request, together with all or that portion of the Registrable Securities of the other Holders, if
joining in that request and as are specified in a written request received by the Corporation within five Business Days after receipt by such other Holders of the written notice from the Corporation referred to in Section 3.1(b)(i).

  

	 	(c)	 Limitations on Registration Obligations. The Corporation shall not be required to effect more than two
Demand Registrations pursuant to this Section 3.1; provided, for greater certainty, that participating in a registration pursuant to the exercise of piggy-back rights by a Holder shall not constitute a Demand Registration; and provided further,
subject to Section 3.2, that a registration shall not constitute a Demand Registration requested under this Section 3.1 unless and until it has become effective and the Initiating Holders are able to register and sell at least 90% of the
Registrable Securities requested to be included in such registration. In addition, the Corporation will not be obligated to take any action to effect any registration pursuant to this Section 3.1 if the Corporation furnishes to the Initiating
Holder a certificate signed by the Chief Executive Officer of the Corporation stating that (a) in the good faith judgment of the Board of Directors of the Corporation, acting reasonably, any such action to effect a registration in the immediate
future would materially interfere with a material bona fide financing, acquisition or other transaction being considered at the time of receipt of the request from the Initiating Holder or would require disclosure of
non-public information, the premature disclosure of which could materially adversely affect the Corporation or materially interfere with such transaction; or (b) the Corporation is engaged in an issuer
bid, self-tender or exchange offer and the proposed registration would cause a violation of applicable Securities Laws (each of (a) and (b), a “Delay Certificate”), then the Corporation’s obligation to file a registration
statement under this Section 3.1 may be deferred, and any time periods with respect to filing 

  
 9 

	 	
or effectiveness thereof shall be tolled accordingly, for a period not to exceed 90 days from the date the Corporation would have been required to file such registration statement after its
receipt of the written request to file such registration statement from the Initiating Holder, provided that the Corporation may not exercise this deferral right more than once in any consecutive 12-month
period. The Corporation shall not be required to effect any Demand Registration pursuant to this Section 3.1 (i) if such request is made within 180 days after the Corporation effects the Initial Offering; (ii) if the Corporation delivers
notice to the holders of Registrable Securities within 30 days of receipt of such request of the Corporation’s intent to file a registration statement for the Initial Offering within 90 days of such notice; (iii) if such securities become
eligible for sale in the U.S. pursuant to Rule 144 under the U.S. Securities Act (“Rule 144”) without the volume or manner-of-sale restrictions and
without the requirement for the Corporation to be in compliance with the current public information requirement under Rule 144(c)(1); or (iv) if such Demand Registration will not cover Registrable Securities having an anticipated aggregate
gross offering price of at least US$50,000,000 (before deduction of underwriters’ commissions and expenses). 

  

	 	(d)	 Underwriting. 

 

	 	(i)	 If the Initiating Holder intends to dispose of the Registrable Securities for which a Demand Registration has
been requested under Section 3.1(a) by means of an underwriting, the Initiating Holder shall so advise the Corporation as part of its request pursuant to Section 3.1(a) and the Corporation will advise the other Holders as part of the
notice given pursuant to Section 3.1(b)(i) that the right of the other Holders to registration pursuant to Section 3.1 will be conditioned upon that Holder’s participation in the underwriting arrangements required by this
Section 3.1(d), and the inclusion of that Holder’s Registrable Securities in the underwriting to the extent requested will be limited to the extent provided in this Agreement. 

 

	 	(ii)	 The Holders of a majority of the Registrable Securities included in any Demand Registration (on an As-Converted Basis) will have the right to select the investment banker(s), underwriter(s), and manager(s) to administer the offering, subject to prior consultation with the Corporation. 

 

	 	(iii)	 The Corporation (together with the Holders proposing or required to distribute their Registrable Securities
through such underwriting) shall enter into an underwriting agreement in customary form with the underwriters selected for that underwriting by the Corporation, acting reasonably, such agreement to be in form and substance satisfactory to the
Holders requesting such registration, acting reasonably, and to contain such representations and warranties and indemnity and contribution provisions by the Corporation and such other terms as are customarily contained in agreements of that type.
Each Holder shall be a party to such underwriting agreement and may, at its option, require that any or all of the representations and warranties by, 

  
 10 

	 	
and the other agreements on the part of, the Corporation to and for the benefit of such underwriters shall also be made to and for the benefit of each Holder and that any or all of the conditions
precedent to the obligations of such underwriters under such underwriting agreement be conditions precedent to the obligations of each Holder. No Holder requesting a Demand Registration shall be required to make any representations or warranties to
or agreements with the Corporation or the underwriters other than representations, warranties or agreements regarding such Holder and its intended method of distribution and any other representation required by the applicable Securities Laws.

  

	 	(iv)	 Notwithstanding any other provision of this Section 3.1, if the underwriters, acting reasonably and in
good faith, determine in writing that, in their opinion, the number of securities to be included in a Demand Registration exceeds the number of securities that can be sold in the offering relating to such Demand Registration and that the number of
securities proposed to be included in the offering in respect of such Demand Registration would adversely affect the price per security to be sold in such offering in respect of such Demand Registration, the underwriters may exclude some or all of
the Registrable Securities from the registration. The Corporation will advise the Holders of Registrable Securities of this exclusion and the number and estimated dollar value of Registrable Securities that may be included in the registration. The
underwriting will be allocated (i) first, among the Holders of Registrable Securities, in respect of their Registrable Securities, on a pro rata basis based on the number of Registrable Securities held by all such Holders calculated on an As-Converted Basis, or in such manner as they otherwise agree, (ii) second, to the Corporation if it elects to participate in such registration, and (iii) third, among any other holders of the securities
to be included in such offering, allocated among such holders pro rata based on the number of securities held by all such holders calculated on an as converted basis or in such manner as they may otherwise agree. In no event shall any Registrable
Securities be excluded from such underwriting unless all other securities are first excluded. 

  

	 	(v)	 If each of the Holders has included all of the Registrable Securities which such Holder desires to include in
that registration, then the Corporation may include additional securities in the registration for sale for the Corporation’s account on the same terms as the Holders’ Registrable Securities, provided the underwriters advise the Corporation
and the Holders in writing that the inclusion does not adversely affect the marketing and the orderly sale of the Holders’ Registrable Securities included in that registration at a price range acceptable to the Holders, acting reasonably. If
the Corporation determines to include Registrable Securities to be sold by it in any registration requests pursuant to this Section 3.1, such registration shall be deemed to have been a Piggy-Back Registration under Section 3.3, and not a
Demand Registration under this Section 3.1. To facilitate the allocation of Registrable Securities in accordance with the above provisions, the Corporation or the underwriters may round the number of Registrable Securities allocated to any
Holder to the nearest appropriate “round number” integral. 

  
 11 

	 	(vi)	 If any Holder disapproves of the terms of the underwriting, such Holder may elect to withdraw from the
underwriting and registration by written notice to the Corporation and the Initiating Holders. Those Registrable Securities of such withdrawing Holder shall continue to be subject to the terms of this Agreement. 

 

	3.2	 Short Form Registrations 

 

	 	(a)	 Request for Registration. If, at any time while the Corporation is eligible to complete a Short Form
Registration, the Corporation shall receive from any one or more of the Holders (in this Section 3.2, the “Initiating Holder”) a written request or requests that the Corporation effect a Short Form Registration with respect to
all or a part of the Registrable Securities owned by such Holder or Holders, the Corporation shall: 

  

	 	(i)	 promptly, and in any event, within three Business Days of receipt, give written notice of the proposed Short
Form Registration to the other Holders offering them the opportunity to participate in such registration with respect to the Registrable Securities held by such other Holders; and 

 

	 	(ii)	 as soon as practicable, but in any event within 45 days after receipt of the request from the Initiating
Holder, file with the applicable Commissions and use its best efforts to effect the registration, qualification or compliance (including, without limitation, filing post-effective amendments, appropriate qualifications under applicable blue sky or
other state securities Laws and appropriate compliance with applicable Securities Laws and any other governmental requirements or regulations) as may be so requested and as would permit or facilitate the sale and distribution of all or that portion
of the Registrable Securities as are specified in the Initiating Holder’s request, together with all or that portion of the Registrable Securities of the other Holders (if any) joining in that request as are specified in a written request
received by the Corporation within five Business Days after receipt by the other Holders of the written notice from the Corporation referred to in Section 3.1(b)(i). The Corporation shall use its best efforts to keep such registration effective
until the earlier of 120 days from the date of effectiveness or until the Holders have completed the distribution described in such registration statement. 

  

	 	(b)	 Limitations on Short Form Registration Obligations. The Corporation shall not be required to complete
any Short Form Registration pursuant to this Section 3.2: 

  

	 	(i)	 if the Corporation is not eligible to complete a Short Form Registration pursuant to applicable Securities
Laws; 

  
 12 

	 	(ii)	 if the Holders propose to sell Registrable Securities pursuant to such Short Form Registration such that the
aggregate offering price is less than US$5,000,000; 

  

	 	(iii)	 if the Corporation furnishes a Delay Certificate to the Holders, in which event the Corporation’s
obligation to file a registration statement under this Section 3.2 may be deferred for a period not to exceed 90 days from the date of receipt of the written request to file such registration statement from the Initiating Holder, provided that
the Corporation may not exercise this deferral right more than once in any consecutive twelve-month period; 

  

	 	(iv)	 if the Corporation has, within the twelve-month period preceding the date of such request, already effected two
Short Form Registrations for the Holders pursuant to this Section 3.2; 

  

	 	(v)	 if the request is made within 180 days after the Corporation effects the Initial Offering; or

  

	 	(vi)	 if such Registrable Securities may be sold pursuant to Rule 144 without the volume or manner-of-sale restrictions and without the requirement for the Corporation to be in compliance with the current public information requirement under Rule 144(c)(1).

 For greater certainty, a registration shall not constitute a Short Form Registration requested under this
Section 3.2 unless and until it has become effective and the Initiating Holders are able to register and sell at least 90% of the Registrable Securities requested to be included in such registration. 

 

	 	(c)	 Underwritings. If the Initiating Holder intends to distribute the Registrable Securities covered by its
request by means of an underwriting, it shall so advise the Corporation as a part of its request made pursuant to Section 3.2(a) and the Corporation shall include such information in the written notice referred to in Section 3.2(a)(i). The
provisions of Section 3.1(d) shall be applicable to such request mutatis mutandis. 

  

	3.3	 Piggy-Back Registrations 

 

	 	(a)	 Notice of Registration. If at any time or from time to time the Corporation determines to register any
of its securities (other than pursuant to a Registration Statement on Form S-8, Form S-4 or Form F-4 or their successors or any
other form for a similar limited purpose, or any registration statement covering only securities in exchange for securities or assets of another corporation), either for its own account or the account of a security holder or holders or both (other
than pursuant to a Demand Registration requested under Section 3.1 or a Short Form Registration required under Section 3.2) including any Initial Offering, on each occasion the Corporation shall: 

  
 13 

	 	(i)	 promptly, and in any event, within three Business Days of such determination, give written notice of the
proposed registration to each of the Holders (each such registration, a “Piggy-Back Registration”), provided such notice must be given no later than 30 days prior to the filing of the registration statement by the Corporation in
connection with such registration; and 

  

	 	(ii)	 include in that registration (and any related qualification or compliance under applicable blue sky Laws or
other state securities Laws or other Securities Laws), and use its best efforts to include in any underwriting involved in the registration, all or any portion of the Registrable Securities specified in a written request made by any of the Holders
and received by the Corporation within 15 Business Days after receipt by such Holder of the written notice delivered by the Corporation pursuant to Section 3.3(a)(i). Such written request may specify that such Holder wishes to include all or a
part of the Holder’s Registrable Securities. 

  

	(b)	 Underwriting. 

 

	 	(i)	 If the Piggy-Back Registration of which the Corporation gives notice pursuant to Section 3.3(a)(i) is for
a registered offering involving an underwriting, the Corporation will so advise each of the Holders as a part of such written notice. In such event, the right of any Holder to registration pursuant to this Section 3.3 will be conditioned upon
that Holder’s participation in the underwriting arrangements required by this Section 3.3(b) and the inclusion of that Holder’s Registrable Securities in the underwriting to the extent requested will be limited to the extent provided
in this Agreement. 

  

	 	(ii)	 In any Piggy-Back Registration initiated by the Corporation, the Corporation will have the right to select the
investment banker(s), underwriter(s), and manager(s) to administer the offering, subject to the approval of the Holders of a majority of the Registrable Securities included in such registration (on an
As-Converted Basis), which in each case will not be unreasonably withheld. 

  

	 	(iii)	 The Holders proposing to distribute their securities through such underwriting will (together with the
Corporation and the other shareholders distributing their securities through that underwriting) enter into an underwriting agreement in customary form with the underwriters, such agreement to be in form and substance satisfactory to all shareholders
requesting such registration, acting reasonably, and to contain such representations and warranties and indemnity and contribution provisions by the Corporation and such other terms as are customarily contained in agreements of that type. Each such
shareholder (including the Holders) shall be a party to such underwriting agreement and may, at its option, require that any or all of the representations and warranties by, and the other

  
 14 

	 	
agreements on the part of, the Corporation to and for the benefit of such underwriters shall also be made to and for the benefit of each such Holder and that any or all of the conditions
precedent to the obligations of such underwriters under such underwriting agreement be conditions precedent to the obligations of each such Holder. No Holder requesting a registration shall be required to make any representations or warranties to or
agreements with the Corporation or the underwriters other than representations, warranties or agreements regarding such Holder and its intended method of distribution and any other representation required by the applicable Securities Laws.

  

	 	(iv)	 Notwithstanding any other provision of this Section 3.3, if the underwriters and the Corporation, acting
reasonably and in good faith, together determine in writing that, in their opinion, the number of securities to be included in the offering relating to such Piggy-Back Registration exceeds the number of securities that can be sold in such offering
and that the number of securities proposed to be included in such offering would adversely affect the price per security to be sold in such offering, the Corporation shall be required to include in the offering only that number of such Registrable
Securities that the underwriters and the Corporation determine, acting reasonably and in good faith, will not jeopardize the success of the offering. The Corporation will advise the Holders of Registrable Securities distributing their securities
through such underwriting of this exclusion and the number and estimated dollar value of the Holders’ securities that may be included in the registration. The underwriting will be allocated (i) first, to the Corporation (but only if it
initiates such offering failing which the priority set forth in Section 3.1(d)(iv) shall apply), (ii) second, among the Holders of Registrable Securities, in respect of their Registrable Securities, on a pro rata basis based on the number of
Registrable Securities held by all such Holders calculated on an As-Converted Basis, or in such manner as they may otherwise agree, and (iii) third, among all other holders of the securities to be
included in such offering, allocated among such holders pro rata based on the number of securities held by all such holders calculated on an as converted basis or in such manner as they may otherwise agree; provided in each case that, unless the
registration is in respect of the Initial Offering, in no event shall the Registrable Securities owned by the Holders included in such underwriting be reduced below 30% of the total number of securities included in such underwriting. To facilitate
the allocation of Registrable Securities in accordance with the above provisions, the Corporation may round the number of Registrable Securities allocated to any Holder to the nearest appropriate “round number” integral.

  

	 	(v)	 If a Holder disapproves of the terms of the underwriting, such Holder may elect to withdraw from that
underwriting by written notice to the Corporation, the other Holders, the underwriters and the other participating shareholders. Any Registrable Securities of such withdrawing Holder excluded or withdrawn from that underwriting will be withdrawn
from registration, and will continue to be subject to the terms of this Agreement. 

  
 15 

	 	(c)	 Right to Terminate Registration. The Corporation has the right to terminate or withdraw any registration
initiated by it under this Section 3.3 prior to the effectiveness of the registration whether or not any Holder or other shareholder has elected to include securities in that registration. The Corporation shall have no liability to any Holder
in respect of such withdrawal other than in respect of the reasonable pro-rata Registration Expenses incurred by any Holder if such Holder has elected to include securities in that registration.

  

	3.4	 Transfer of Registration Rights 

The rights to cause the Corporation to register securities granted to any Holder under Sections 3.1, 3.2, and 3.3 may (if agreed to by such
Holder) be transferred or assigned to a transferee or assignee to whom a Holder transfers or assigns (A) not less than 1,000,000 (subject to adjustments for stock dividends, splits, combinations and similar events) of such Holder’s
Registrable Securities (other than a transfer under Rule 144 of the U.S. Securities Act or a registration effected pursuant to this Agreement or any other transfer under which securities will cease to be Registrable Securities), or (B) all or
part of such Holder’s Registrable Securities where such transferee or assignee is (i) a Subsidiary or Affiliate of such Holder or, where the Holder is a limited or general partnership, where such transferee or assignee is a constituent
Affiliated limited or general partner or retired partner of the Holder or an Affiliated partnership, (ii) a Major Investor, (iii) any member or former member of any Holder, where the Holder is a limited liability company, or
(iv) any family member or trust for the benefit of any Holder, where the Holder is an individual; in each case provided, that: (i) the transfer may otherwise be effected in accordance with applicable Securities Laws and the Shareholders
Agreement; (ii) the Corporation is given written notice at least three Business Days prior to such transfer stating the name and address of the transferee and identifying the securities with respect to which such registration rights are being
transferred; (iii) the transferee agrees in writing to be bound by the provisions of this Agreement and, to the extent required under the Shareholders’ Agreement, by the provisions of the Shareholders Agreement; and (iv) the total
number of registrations to be exercised by all persons under this Agreement may not be increased other than in accordance with the terms of this Agreement. 
  

	3.5	 Co-operation 

Each Holder requesting inclusion of Registrable Securities in a registration statement will furnish to the Corporation information regarding
such Holder as the Corporation, acting reasonably, may from time to time request in writing, and will do such reasonable acts and things as the Corporation may from time to time request, with respect to any registration, qualification or compliance
referred to in this Agreement and in order to permit the Corporation to comply with the requirements of applicable Laws. 

  
 16 

	3.6	 Termination of Registration Rights 

All obligations of the Corporation (except those pursuant to Article 6) shall terminate and be of no further force and effect on the date which
is the earlier of (i) the closing of a Liquidation Event, as such term is defined in the Articles of Incorporation; (ii) such time after the consummation of a Qualified IPO as Rule 144 or another similar exemption under the Securities Act
is available for the sale of all such Holder’s shares without limitation during a three-month period without registration,; or (iii) the date which is three years after the date of completion of a Qualified IPO (as such term is defined in
the Articles of Incorporation). 
  

	3.7	 Limitations on Subsequent Registration Rights. 

From and after the date of this Agreement, the Corporation shall not, without the prior written consent of the Holders of the majority of
Registrable Securities, on an As-Converted Basis, (i) enter into any other agreement with any holder or prospective holder of any securities of the Corporation which would allow such holder or prospective
holder to participate in any registration of securities of the Corporation or (ii) enter into any agreement, take any action, or permit any change to occur, with respect to its securities that violates, subordinates or otherwise affects the
rights granted to the Holders of the Registrable Securities in this Agreement. 
 ARTICLE 4 

ADDITIONAL PROVISIONS FOR REGISTRATIONS 
  

	4.1	 Rule 144 Reporting and Form S-3, Form
F-3 and Form F-10 Requirements 

 With
a view to making available the benefits of certain rules and regulations of the SEC which may at any time permit the sale of the Registrable Securities to the public in the United States without registration, or pursuant to a registration on Form S-3, Form F-3 or Form F-10, including, without limitation, Rule 144 under the U.S. Securities Act, the Corporation agrees at its
expense, but only if and to the extent that the Initial Offering was completed in the United States or the Corporation has otherwise registered securities under the U.S. Exchange Act: 

 

	 	(a)	 to make and keep public information available, as those terms are understood and defined in Rule 144 under the
U.S. Securities Act, at all times after the date that the Corporation becomes subject to the reporting requirements of the U.S. Exchange Act; 

  

	 	(b)	 to file with the SEC in a timely manner all reports and other documents required of the Corporation under the
U.S. Securities Act and the U.S. Exchange Act (at any time after it has become subject to such reporting requirements); and 

  

	 	(c)	 so long as any Holder owns any Registrable Securities, to furnish to the Holders, promptly upon request, a
written statement by the Corporation as to its compliance with the reporting requirements of Rule 144 under the U.S. Securities Act (at any time after the Corporation becomes subject to the reporting requirements of the U.S. Exchange Act), a copy of
the most recent annual or quarterly report of the Corporation, and any other reports and documents of the Corporation and other information in the possession of or reasonably obtainable by the Corporation as any Holder may reasonably request in
availing itself of any rule or regulation of the SEC allowing the Holders to sell any securities without registration or pursuant to such form. 

  
 17 

	4.2	 NI 44-101 and NI 51-102
Requirements 

 With a view to making available the benefits of certain Canadian Securities Laws which may at any time
permit the sale of the Registrable Securities to the public in any one or more province and territory of Canada without registration, or pursuant to a short form Canadian Prospectus in the form of Form
44-101F1 pursuant to NI 44-101, upon the completion of the Initial Offering, the Corporation agrees to, at its expense, but only if and to the extent that the Initial
Offering was completed in Canada or the Corporation has otherwise become a “reporting issuer” in any province of territory of Canada, meet the eligibility criteria set out in NI 44-101 for the use of
a short form prospectus in connection with the sale of its securities by, among other things, filing an initial annual information form and all renewal annual information forms, as all as other relevant and applicable continuous disclosure documents
with the applicable Commissions pursuant to the requirements of NI 44-101 and NI 51-102. 

ARTICLE 5 
 REGISTRATION
PROCEDURES AND EXPENSES 
  

	5.1	 Registration Procedures 

In the case of each registration effected by the Corporation pursuant to this Agreement, the Corporation will keep each Holder advised in
writing as to the initiation of each registration and as to the completion of that registration. The Corporation shall at its expense and as expeditiously as is practicable: 
  

	 	(a)	 subject to Sections 3.1(b) and 3.2(a)(ii), prepare and file with the applicable Commissions a registration
statement with respect to those Registrable Securities and use its best efforts to cause that registration statement to become and remain effective for at least 180 days (or 120 days in the case of a Short Form Registration) or until the
distribution described in the registration statement has been completed, whichever occurs first; provided, however, that: (i) such 180-day period (or 120-day period
in the case of a Short Form Registration) shall be extended for a period of time equal to the period between the time that the Corporation notifies the Holders of the happening of any event described in Section 5.1(g) and the time that the
Corporation provides the Holders with a corrective supplement or amendment pursuant to such Section; and (ii) in the case of any Short Form Registration, which are intended to be offered on a continuous or delayed basis, such 120-day period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold, provided that Rule 415 under the U.S. Securities Act (or any successor
rule) or Canadian Securities Laws, as applicable, permit an offering on a continuous or delayed basis, and provided further that applicable rules under the U.S. Securities Act or Canadian Securities Laws, as applicable, governing the obligation to
file a post-effective amendment permit the incorporation by reference in the registration statement of information required to be included in (x) and below, to be contained in periodic reports filed pursuant to

  
 18 

	 	
Section 13 or 15(d) of the U.S. Exchange Act or NI 51-102, as applicable, in lieu of filing a post-effective amendment that: (x) includes any
prospectus required by Section 10(a)(3) of the U.S. Securities Act, or (y) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement; 

 

	 	(b)	 prepare and file with the applicable Commissions such amendments (including post-effective amendments) and
supplements to such registration statement and the prospectus used in connection with such registration statement, as may be necessary to comply with the provisions of the Securities Laws and this Agreement with respect to the disposition of all
Registrable Securities covered by such registration statement; 

  

	 	(c)	 furnish to the Holders participating in such registration and to the underwriters of the Registrable Securities
being registered such numbers of copies of the registration statement, preliminary prospectus, final prospectus (including all documents incorporated by reference therein) and any other documents as such Holders and underwriters may reasonably
request in order to facilitate the public offering of those securities; 

  

	 	(d)	 use its best efforts to register and qualify the Registrable Securities covered by such registration statement
under such other state or provincial securities Laws or blue sky Laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Corporation shall not be required in connection therewith or as a condition thereto to
qualify to do business or to file a general consent to service of process in any such states or provinces or jurisdictions or subject itself to taxation in any such jurisdiction; 

 

	 	(e)	 in the event of any underwritten public offering, enter into and perform its obligations under an underwriting
agreement, in usual and customary form, with the underwriters of such offering; 

  

	 	(f)	 notify each selling Holder of Registrable Securities, promptly after the Corporation receives notice thereof,
of the time when a registration statement relating to such Holders’ Registrable Securities has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; 

 

	 	(g)	 as soon as possible after becoming aware of such an event notify each Holder of Registrable Securities covered
by such registration statement at any time when a prospectus relating thereto is required to be delivered under the applicable Securities Laws, of the happening of any event as a result of which the prospectus included in such registration
statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing
or if it is necessary to amend or supplement such prospectus to comply with the Securities Laws (a “10b-5 Event”), and to use its best efforts to promptly prepare a supplement or amendment of such
document 

  
 19 

	 	
correcting such untrue statement or eliminate such omission and so that such document, as amended or supplemented, will comply with the applicable Securities Laws (a “10b-5 Correction”), and furnish to each Holder as many copies of such supplement or amendment as each such Holder may request; provided, further, that each Holder of Registrable Securities
that is aware of a 10b-5 Event shall not sell its Registrable Securities until a 10b-5 Correction; 

 

	 	(h)	 use its best efforts to cause all such Registrable Securities registered pursuant to this Agreement to be
listed on each securities exchange or national market system, if any, on which similar securities issued by the Corporation are then listed or, if the Corporation’s securities are not then listed, on a securities exchange or national market
system selected by the Holders of a majority of the Registrable Securities (on an As-Converted Basis); 

  

	 	(i)	 provide a transfer agent and registrar for all Registrable Securities registered pursuant hereunder and provide
a CUSIP number for all Registrable Securities, in each case, not later than the effective date of such registration; 

  

	 	(j)	 at the request of any Holder requesting registration of Registrable Securities pursuant to a Demand
Registration, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a Demand Registration, if such securities are being sold through underwriters, use its best efforts to cause to be delivered:
(i) an opinion, dated such date, of the counsel representing the Corporation (including an opinion from each local state, provincial and/or territorial counsel in each of the jurisdictions in which the registration is effected) for the purposes
of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters and to the Holders requesting registration of Registrable Securities; (ii) a letter dated such
date, from the auditors of the Corporation, in form and substance as is customarily given by auditors to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of
Registrable Securities; and (iii) such corporate certificates and other documents and instruments, each dated such date, as are customarily furnished to underwriters in an underwritten public offering or as such Holder may otherwise reasonably
request, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities; 

  

	 	(k)	 use its best efforts to prevent the issuance of any stop order or other suspension of effectiveness of a
registration statement, and, if such an order is issued, to obtain the withdrawal of such order at the earliest possible moment and to notify each Holder who holds Registrable Securities being sold (or, in the event of an underwritten offering, the
underwriters) of the issuance of such order and the resolution thereof; 

  
 20 

	 	(l)	 in connection with the preparation and filing of each registration statement pursuant to this Article 5, give
each Holder who holds Registrable Securities being sold, and its counsel, accountants and other agents, the opportunity to participate, acting reasonably, in the preparation of the registration statement, and each amendment thereof or supplement
thereto, and will give each of them such access to its books and records and such opportunities to discuss the business of the Corporation with its directors, officers, key employees, attorneys, consultants and the independent public accountants of
the Corporation who have issued a report on its financial statements as shall be necessary, in the opinion of such Holders and such underwriters or their respective counsel, to conduct a reasonable investigation; 

 

	 	(m)	 hold in confidence and not make any disclosure of information concerning a Holder provided to the Corporation
unless: (i) disclosure of such information is necessary to comply with Securities Laws; (ii) the disclosure of such information is necessary to avoid or correct a misstatement or omission in any registration statement; (iii) the
release of such information is ordered pursuant to a subpoena or other order from a court or governmental body of competent jurisdiction; or (iv) such information has been made generally available to the public other than by disclosure in
violation of this Agreement or any other agreement. The Corporation agrees that it shall, upon learning that disclosure of such information concerning a Holder is sought in or by a court or governmental body of competent jurisdiction or through
other means, give prompt notice to such Holder prior to making such disclosure, and allow the Holder, at its expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information;

  

	 	(n)	 promptly make available for inspecting by the selling Holders, any managing underwriter(s) participating in any
disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of
the Corporation, and cause the Corporation’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary
or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

  

	 	(o)	 within a reasonable time before each filing of the registration statement or prospectus or amendments or
supplements thereto with the applicable Commissions, furnish to one counsel, selected by the majority of holders of Registrable Securities included in such registration (on an As-Converted Basis), copies of
such documents proposed to be filed, which documents shall be subject to the approval of such counsel with such approval not to be unreasonably withheld or delayed; 

 

	 	(p)	 otherwise use its best efforts to comply with all applicable rules and regulations of each applicable
Commission and make generally available to its security holders, in each case as soon as practicable, but not later than 30 days after the close of the period covered thereby, an earnings statement of the Corporation which will satisfy the
provisions of Section 11(a) of the U.S. Securities Act and Rule 158 thereunder (or any comparable successor provisions); 

  
 21 

	 	(q)	 in connection with an underwritten offering, participate, to the extent reasonably requested by the managing
underwriter for the offering or the Holders, in customary efforts to sell the securities being offered, and cause such steps to be taken as to ensure such good faith participation of senior management officers of the Corporation in “road
shows” as is customary; 

  

	 	(r)	 permit any Holder of Registrable Securities which holder, in its sole and exclusive judgment, might be deemed
to be an “underwriter” (as such term is defined in the applicable Securities Laws) or a “controlling person” (as such term is defined in the applicable Securities Laws) of the Corporation, to participate in the preparation of
such registration statement and to require the insertion therein of language furnished to the Corporation in writing, which in the reasonable judgment of such Holder and its counsel should be included; and 

 

	 	(s)	 otherwise use its best efforts to take all other steps necessary to effect the registration of such Registrable
Securities contemplated hereby. 

  

	5.2	 Expenses of Registration 

All Registration Expenses will be borne by the Corporation, including the fees of one special counsel of the Holder of Registrable Securities
in an amount not to exceed US$35,000 (plus disbursements and applicable taxes) for each registration undertaken pursuant to this Agreement; provided, however, that the Corporation shall not be required to pay for Selling Expenses relating to
Registrable Securities. In addition, if requested by one or more Major Investors, the Corporation shall bear the reasonable fees, expenses and disbursements of one special counsel of the Major Investors in connection with the Initial Offering in an
amount not to exceed US$50,000 (plus applicable taxes), whether or not any of the Registrable Securities are included in the Initial Offering. 

ARTICLE 6 

INDEMNIFICATION 
  

	6.1	 Indemnification Provided by the Corporation in Favour of the Holders 

In the event any Registrable Securities are included in a registration statement under this Agreement, the Corporation will indemnify, to the
extent permitted by applicable law, each Holder that participates in such offering, each of its officers and directors and partners (or, in the case of a Holder that is a limited partnership, each of the partners and the officers and directors of
the general partner of the limited partnership and its affiliates), each person controlling any Holder within the meaning of Section 15 of the U.S. Securities Act or Section 20 of the U.S. Exchange Act, and each underwriter, if any, and
each person who controls any underwriter within the meaning of Section 15 of the U.S. Securities Act or Section 20 of the U.S. Exchange Act (collectively, the “Holder Indemnified Parties”), against all expenses, claims,
losses, damages and liabilities (or actions in respect of expenses, claims, losses, damages or liabilities), including any of the foregoing incurred in settlement of any litigation, commenced or threatened, arising out of or based on
(i) any untrue statement (or alleged untrue statement) of a material fact contained in any registration statement, prospectus, offering circular “free writing prospectus” (as defined in

  
 22 

 
Rule 405 under the U.S. Securities Act) or other document, or any amendment or supplement to any document, incident to the registration, qualification or compliance, or (ii) any omission (or
alleged omission) to state in a document a material fact required to be stated or necessary to make the statements, in light of the circumstances in which they were made, not misleading, or any violation by the Corporation of the U.S. Securities
Laws, the Canadian Securities Laws, or any rule or regulation promulgated under any Laws applicable to the Corporation in connection with any registration, qualification or compliance, and in each case the Corporation will reimburse
each of such Holder Indemnified Parties, for any legal and any other expenses reasonably incurred, as such expenses are incurred, in connection with investigating, preparing or defending any such claim, loss, damage, liability or action,
provided, however, that the indemnity contained in this Section 6.1 will not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the
Corporation, which consent will not be unreasonably withheld and provided that the Corporation will not be liable in any case to the extent that any claim, loss, damage, liability or expense arises out of or is based on any untrue statement or
omission or alleged untrue statement or omission, made in reliance upon and in conformity with written information furnished to the Corporation by any Holder, controlling person thereof or underwriter to be specifically for use in any such document;
and provided further, however, that the foregoing indemnity is subject to the condition that, insofar as it relates to any untrue statement, alleged untrue statement, omission or alleged omission made in a prospectus on file with the Commissions at
the time the registration statement becomes effective or the amended prospectus filed with the SEC pursuant to Rule 424(b) under the U.S. Securities Act (the “Final Prospectus”), that indemnity will not enure to the benefit of any
underwriter or any Holder, if there is no underwriter, if any such underwriter or Holder failed to furnish a copy of the Final Prospectus to the person asserting the loss, liability, claim or damage at or prior to the time the action is required by
the applicable Securities Laws, and if the Final Prospectus would have cured the defect giving rise to the loss, liability, claim or damage. The indemnification provided for under this Section 6.1 shall remain in full force and effect
regardless of any investigation made by or on behalf of any of the Holder Indemnified Parties and shall survive the transfer of the Registrable Securities by the Investors and their transferees. 

 

	6.2	 Indemnification Provided by the Holders in Favour of the Corporation 

In the event any Registrable Securities are included in a registration statement under this Agreement, each Holder will, if Registrable
Securities held by that Holder are included in the securities as to which the registration, qualification or compliance is being effected, indemnify, to the extent permitted by applicable law, the Corporation, each of its directors and officers,
each underwriter, if any, of the Corporation’s securities covered by that registration statement, each person who controls the Corporation or the underwriter within the meaning of Section 15 of the U.S. Securities Act or Section 20 of
the U.S. Exchange Act, and the other Holders selling securities in such registration statement, each of its officers and directors and partners (or, in the case of a Holder that is a limited partnership, each of the partners and the officers and
directors of the general partner of the limited partnership and its affiliates) and each person controlling such other Holders within the meaning of Section 15 or Section 20 of the U.S. Securities Act, against all expenses, claims, losses,
damages and liabilities (or actions in respect of expenses, claims, losses, damages and liabilities), including any of the foregoing incurred in settlement of any litigation, commenced or threatened, arising out of or based on
(i) any untrue statement (or alleged untrue statement), of a material fact contained in any registration statement, prospectus, offering circular, “free writing 

  
 23 

 
prospectus” (as defined in Rule 405 under the U.S. Securities Act) or other document, or any amendment or supplement to any document incident to the registration, qualification or
compliance, or (ii) any omission (or alleged omission) to state in a document a material fact required to be stated or necessary to make the statements, in light of the circumstances in which they were made, not misleading, in each case
to the extent, but only to the extent, that each untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in a registration statement, prospectus, offering circular or other document in reliance upon
and in conformity with written information furnished to the Corporation by the Holder and to be specifically for use in any such document, and in each case such Holder will reimburse the Corporation, the other Holders, the directors,
officers, partners, underwriters or control persons for any legal or any other expenses reasonably incurred, as such expenses are incurred, in connection with investigating or defending any claim, loss, damage, liability or action, provided,
however, that the indemnity contained in this Section 6.2 will not apply to amounts paid in settlement of any loss, claim, damage, liability or action if the settlement is effected without the consent of the Holder, which consent will
not be unreasonably withheld; provided, that the obligation to indemnify under this Section 6.2 shall be several, not joint and several, for each Holder and shall be limited to the net proceeds (after underwriting fees, commissions or
discounts) actually received by such Holder from the sale of the Registrable Securities pursuant to such registration. 
  

	6.3	 Indemnification Procedure 

 

	 	(a)	 Each party entitled to indemnification under this Article 6 (the “Indemnified Party”) will
give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after that Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and, if the Indemnifying Party
acknowledges its liability hereunder, will permit the Indemnifying Party to assume the defense of any claim or any litigation, provided that counsel for the Indemnifying Party, who will conduct the defense of the claim or litigation, will be
approved by the Indemnified Party (whose approval will not be unreasonably withheld), and the Indemnified Party may participate in the defense at that party’s expense, and provided further that the failure of any Indemnified Party to give
notice as provided in this Agreement will not relieve the Indemnifying Party of its obligations under this Agreement unless the failure to give the notice is materially prejudicial to an Indemnifying Party’s ability ‘to defend that action
and provided further, that the Indemnifying Party will not assume the defense for matters in which there is, in the reasonable opinion of outside counsel to the Indemnified Party, a conflict of interest or separate and different defenses. No
Indemnifying Party, in the defense of any such claim or any resulting litigation, will, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term
from the claimant or plaintiff to the Indemnified Party of a release from all liability in respect of the claim or litigation. 

  

	 	(b)	 If the indemnification provided for in this Article 6 is held by a court of competent jurisdiction to be
unavailable to an Indemnified Party with respect to any loss, liability, claim, damage, or expense referred to herein, then the Indemnifying Party, in lieu of indemnifying the Indemnified Party hereunder, will contribute to the

  
 24 

	 	
amount paid or payable by the Indemnified Party as a result of the loss, liability, claim, damage, or expense in the proportion as is appropriate to reflect the relative fault of the Indemnifying
Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions that resulted in the loss, liability, claim, damage, or expense as well as any other relevant equitable considerations. The relative fault
of the Indemnifying Party and of the Indemnified Party will be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied
by the Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent the statement or omission, provided however, that, in any case, (i) no Holder
will be required to contribute any amount in excess of the gross proceeds of all the Registrable Securities offered and sold by the Holder pursuant to the registration statement that are received by such Holder; and (ii) no person or entity
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the U.S. Securities Act) will be entitled to contribution from any person or entity who was not guilty of fraudulent misrepresentation. 

 

	 	(c)	 The obligations of the Corporation and the Holders under this Article 6 shall survive the completion of any
offering of Registrable Securities in a registration statement under Article 3 of this Agreement. 

 ARTICLE 7 

GENERAL PROVISIONS 
  

	7.1	 Notices 

All notices provided for in this Agreement (“Notices”) shall be in writing and will be sufficiently given if delivered (by
hand, by overnight international courier service), or if by e-mail to the following addresses: 
  

	 	(a)	 in the case of a Notice to the Corporation at: 

 

	
	 REPARE THERAPEUTICS INC.

7210 Frederick-Banting Street

Suite 100
 Saint-Laurent
(Québec) H4S 2A1
  
 Attention: Lloyd Segal

Email:
  

With a copy to (which copy shall not constitute a Notice to the Corporation):

 
 STIKEMAN ELLIOTT LLP

1155 René-Lévesque Blvd. West

41st Floor

Montréal, Québec H3B 3V2

Attention: Sidney Horn and Jeremy Sculnick

Email:

  
 25 

	 	(b)	 in the case of any Holder, at the address, e-mail address contained in
Schedule A or Schedule B or, if not set out in Schedule A or Schedule B, to the most recent address or e-mail address known to the Person sending the Notice. 

Any Notice delivered or transmitted to a party as provided above is deemed to have been given and received on the day it is delivered or
transmitted if it is delivered or transmitted on a Business Day prior to 5:00 p.m. local time in the place of delivery or receipt. If the Notice is delivered or transmitted after 5:00 p.m. local time or if such day is not a Business Day, then the
Notice is deemed to have been given and received on the next Business Day. Any Notice given by e-mail shall also promptly be given by hand delivery or overnight international courier service. Any party may,
from time to time, change its address by giving Notice to the other parties in accordance with the provisions of this Section 7.1. 
  

	7.2	 Enurement 

This Agreement shall enure to the benefit of and be binding upon the parties hereto and their respective successors. This Agreement shall be
binding upon any assigns, and enure to the benefit of any permitted assigns, of each party hereto. 
  

	7.3	 Counterparts 

This Agreement may be executed in one or more counterparts (whether by facsimile signature or otherwise), each of which shall be deemed an
original and all of which, taken together, shall constitute one and the same instrument. 
  

	7.4	 Assignment 

Except as otherwise provided herein, none of the rights or obligations hereunder shall be assignable or transferable by any party without the
prior written consent of the other parties. 
  

	7.5	 Entire Agreement 

This Agreement constitutes the entire agreement between the parties hereto pertaining to the subject matter of this Agreement. This Agreement
annuls and replaces any prior or current registration rights agreement entered into between the Holders (or any of them) and the Corporation, including the Original Registration Rights Agreement. 

 

	7.6	 Amendments, Modifications, etc. 

This Agreement may not be amended, modified or waived except by written agreement of the Corporation and Holders holding at least 60% of the
then-outstanding Registrable Securities (on an As-Converted Basis). No waiver of any provision of this Agreement shall constitute a waiver of any other provision nor shall any waiver of any provision of this
Agreement constitute a continuing waiver unless otherwise expressly provided. 

  
 26 

	7.7	 Additional Parties 

The parties acknowledge that, subsequent to the date of this Agreement, the Corporation may, subject to compliance with the Shareholders
Agreement, issue additional shares in the capital of the Corporation to one or more permitted transferees of the Investors, as described in Sections 3.5, 3.6 and 3.7 of the Shareholders Agreement as amended and restated on the date hereof or as
described in any successor provision of the Shareholders Agreement, as it may be amended and restated from time to time, relating to permitted transferees of the Investors (the “Additional Parties”). Without needing the consent of
any of the parties hereto (whether pursuant to Section 3.7 or 7.6 or otherwise), each such Additional Party may become a party to this Agreement by executing a counterpart signature page substantially in the form attached as Schedule C and
acceptance by the Corporation of such counterpart signature page as signified by its execution thereof. Upon execution and delivery of the counterpart signature page and acceptance by the Corporation, such Additional Party will be a party to this
Agreement as an Investor and be subject to the terms and conditions of this Agreement as if it were an original signatory. 
  

	7.8	 Further Assurances 

Each of the parties hereto shall promptly do, make, execute or deliver, or cause to be done, made, executed or delivered, all such further
acts, documents and things as the other party hereto may reasonably require from time to time for the purpose of giving effect to this Agreement and shall use reasonable efforts and take all such steps as may be reasonably within its power to
implement to their full extent the provisions of this Agreement. 
  

	7.9	 Specific Performance 

The Corporation recognizes that the rights of the Holders under this Agreement are unique, and, accordingly, the Holders will, in addition to
such other remedies available to them at law or in equity, have the right to enforce their rights under this Agreement by actions for injunctive relief and specific performance to the extent permitted by law. This Agreement is not intended to limit
or abridge any rights of the Holders that exist apart from this Agreement. 
 [THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.]

  
 27 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement by their respective
officers thereunto duly authorized. 
  

			
	VERSANT VENTURE CAPITAL V, L.P.
	
	By Its General Partner
	VERSANT VENTURES V, LLC
		
	By:	 	 /s/ Jerel C. Davis

		 	Name: Jerel C. Davis
		 	Title: Agent

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	 VERSANT VENTURE CAPITAL VI, L.P.
  

By Its General Partner
 VERSANT VENTURES VI GP,
L.P.,
  
 By Its General Partner

VERSANT VENTURES VI GP-GP, LLC

		
	By:	 	 /s/ Jerel C. Davis

		 	Name: Jerel C. Davis
		 	Title: Managing Director

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	 VERSANT AFFILIATES FUND V, L.P.
  

By Its General Partner
 VERSANT VENTURES V,
LLC

		
	By:	 	 /s/ Jerel C. Davis

		 	Name: Jerel C. Davis
		 	Title: Agent

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	 VERSANT OPHTHALMIC AFFILIATES
FUND I, L.P.
  

By Its General Partner
 VERSANT VENTURES V,
LLC

		
	By:	 	 /s/ Jerel C. Davis

		 	 Name: Jerel C. Davis
 Title: Agent

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	VERSANT VENTURE CAPITAL V
(CANADA) LP
		
	By	 	Its General Partner
	VERSANT VENTURES V (CANADA), L.P.
		
	By	 	Its General Partner
	VERSANT VENTURES V GP-GP
(CANADA), INC.
		
	By:	 	 /s/ Jerel C. Davis

		 	 Name: Jerel C. Davis
 Title: Agent

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	 VERSANT VANTAGE I, L.P.
  

By Its General Partner
 VERSANT VANTAGE I GP,
L.P.,
  
 By Its General Partner

VERSANT VANTAGE I GP-GP, LLC

		
	By:	 	 /s/ Jerel C. Davis

		 	 Name: Jerel C. Davis
 Title: Managing
Director

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	MPM BIOVENTURES 2014, L.P.
		
	By:	 	 MPM BIOVENTURES 2014 GP LLC,
 its
general partner

		
	By:	 	 MPM BIOVENTURES 2014 LLC,
 its
managing member

		
	By:	 	 /s/ Kristen Laguerre

		 	 Name: Kristen Laguerre
 Title:Managing Director,
Finance

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	MPM BIOVENTURES 2014 (B), L.P.
		
	By:	 	 MPM BIOVENTURES 2014 GP LLC,
 its
general partner

		
	By:	 	 MPM BIOVENTURES 2014 LLC,
 its
managing member

		
	By:	 	 /s/ Kristen Laguerre

		 	 Name: Kristen Laguerre
 Title: Managing
Director, Finance

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	MPM ASSET MANAGEMENT
INVESTORS BV2014 LLC
		
	By:	 	 MPM BIOVENTURES 2014 LLC,
 its
manager

		
	By:	 	 /s/ Howard Rubin

		 	 Name: Howard Rubin
 Title: Authorized
Signatory

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	UBS ONCOLOGY IMPACT FUND, L.P.
		
	By:	 	 ONCOLOGY IMPACT FUND
 (CAYMAN)
MANAGEMENT L.P.,
 its general partner

		
	By:	 	 MPM ONCOLOGY IMPACT
 MANAGEMENT
LP,
 its general partner

		
	By:	 	 MPM ONCOLOGY IMPACT
 MANAGEMENT GP
LLC,
 its general partner

		
	By:	 	 /s/ Kristen Laguerre

		 	 Name: Kristen Laguerre
 Title: Managing
Director, Finance

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	BDC CAPITAL INC.
		
	By:	 	 /s/ Jean-Francois Pariseau

		 	 Name: Jean-Francois Pariseau
 Title: Partner,
Amplitude Ventures

		
	By:	 	 /s/ Dion Madsen

		 	 Name: Dion Madsen
 Title: Partner, Amplitude
Ventures

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

					
	FONDS DE SOLIDARITÉ DES
TRAVAILLEURS DU QUÉBEC
(F.T.Q.)
		
	By:	 	 /s/ Didier Leconte

		 	 Name:
 Title:
	 	 Didier Leconte
 Vice-President,
Investments,
 Life Sciences

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	CELGENE SWITZERLAND LLC
		
	By:	 	 /s/ Kevin Mello

		 	 Name: Kevin Mello
 Title: Manager

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	 COWEN HEALTHCARE
INVESTMENTS II LP
  

By Its General Partner
 COWEN HEALTHCARE
INVESTMENTS
II GP LLC

		
	By:	 	 /s/ Kevin Raidy

		 	 Name:Kevin Raidy
 Title:  Managing
Partner

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	 CHI EF II LP
  

By Its General Partner
 COWEN HEALTHCARE
INVESTMENTS
II GP LLC

		
	By:	 	 /s/ Kevin Raidy

		 	 Name: Kevin Raidy
 Title:  Managing
Partner

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	 ORBIMED PRIVATE INVESTMENTS VII, LP
  

By Its General Partner
 ORBIMED CAPITAL GP VII
LLC
  
 By Its Managing Member

ORBIMED ADVISORS LLC

		
	By:	 	 /s/ Carl L. Gordon

		 	 Name: Carl L. Gordon

Title:  Member

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	 REDMILE BIOPHARMA INVESTMENTS II, L.P.
  

By Its General Partner
 REDMILE BIOPHARMA INVESTMENTS
II
(GP), LLC

		
	By:	 	 /s/ Christopher O’Connor

		 	 Name: Christopher O’Connor

Title:  Partner

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	 BIOTECHNOLOGY VALUE FUND, LP
  

By Its General Partner
 BVF PARTNERS L.P.

 
 By Its General Partner

BVF INC.

		
	By:	 	 /s/ Mark Lampert

		 	 Name:  Mark Lampert

Title:   President of BVF Inc., General Partner of BVF Partners L.P., itself GP of Biotechnology
Value Fund, LP

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	 BIOTECHNOLOGY VALUE FUND II, LP
  

By Its General Partner
 BVF PARTNERS L.P.

 
 By Its General Partner

BVF INC.

		
	By:	 	 /s/ Mark Lampert

		 	 Name:  Mark Lampert

Title:   President of BVF Inc., General Partner of BVF Partners L.P., itself GP of Biotechnology
Value Fund II, LP

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	 BIOTECHNOLOGY VALUE TRADING
FUND OS, LP
  

By Its General Partner
 BVF PARTNERS OS LTD.

 
 By Its Sole Member

BVF PARTNERS L.P.
  

By Its General Partner
 BVF INC.

		
	By:	 	 /s/ Mark Lampert

		 	 Name:  Mark Lampert

Title:   President of BVF Inc., General Partner of BVF Partners L.P., itself sole member of BVF
Partners OS Ltd., itself GP of Biotechnology Trading Fund OS, L.P.

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	 MSI BVF SPV LLC
  

By Its Attorney-in-fact

BVF PARTNERS L.P.
  

By Its General Partner
 BVF INC.

		
	By:	 	 /s/ Mark Lampert

		 	 Name:  Mark Lampert

Title:   President of BVF Inc., itself General Partner of BVF Partners L.P., itself attorney-in-fact for MSI BVF SPV, L.L.C.

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	 LOGOS OPPORTUNITIES FUND I, L.P.
  

By Its General Partner
 LOGOS OPPORTUNITIES GP,
LLC

		
	By:	 	 /s/ Graham Walmsley

		 	 Name: Graham Walmsley

Title:  Manager

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

			
	REPARE THERAPEUTICS INC.
		
	Per:	 	 /s/ Lloyd M. Segal

	Name:	 	Lloyd M. Segal
	Title:	 	Chief Executive Officer, President and
		 	Secretary

  
 [Signature Page –
Repare Therapeutics Inc. – Amended and Restated Registration Rights Agreement] 

 SCHEDULE A 

CLASS A INVESTORS 

VERSANT VENTURE CAPITAL V, L.P. 

One Sansome Street, Suite 3630 
 San Francisco, CA 94104 

VERSANT OPHTHALMIC AFFILIATES FUND I, L.P. 

One Sansome Street, Suite 3630 
 San Francisco, CA 94104 

VERSANT AFFILIATES FUND V, L.P. 

One Sansome Street, Suite 3630 
 San Francisco, CA 94104 

VERSANT VENTURE CAPITAL V (CANADA) LP 

One Sansome Street, Suite 3630 
 San Francisco, CA 94104 

VERSANT VENTURE CAPITAL VI, L.P. 

One Sansome Street, Suite 3630 
 San Francisco, CA 94104 

MPM BIOVENTURES 2014, L.P. 
 450 Kendall
St. 
 Cambridge, MA, 02142 
 MPM BIOVENTURES
2014 (B), L.P. 
 450 Kendall St. 
 Cambridge, MA, 02142

 MPM ASSET MANAGEMENT INVESTORS BV2014 LLC 

450 Kendall St. 
 Cambridge, MA, 02142 

UBS ONCOLOGY IMPACT FUND, L.P. 

450 Kendall St. 
 Cambridge, MA, 02142 

BDC CAPITAL INC. 
 c/o
Business Development Bank of Canada 
 5 Place Ville Marie 

Bureau 400 
 Montréal, QC H3B 5E7 

 FONDS DE SOLIDARITÉ DES
TRAVAILLEURS DU QUÉBEC (F.T.Q.) 
 545, boul. Crémazie Est 

Bureau 200 
 Montréal, QC H2M 2W4 

CELGENE SWITZERLAND LLC 

AON House 
 30 Woodbourne Ave 

Pemborke HM 08 
 Bermuda 

  
 52 

 SCHEDULE B 

CLASS B INVESTORS 

VERSANT VENTURE CAPITAL V, L.P. 

One Sansome Street, Suite 3630 
 San Francisco, CA 94104 

VERSANT OPHTHALMIC AFFILIATES FUND I, L.P. 

One Sansome Street, Suite 3630 
 San Francisco, CA 94104 

VERSANT AFFILIATES FUND V, L.P. 

One Sansome Street, Suite 3630 
 San Francisco, CA 94104 

VERSANT VENTURE CAPITAL V (CANADA) LP 

One Sansome Street, Suite 3630 
 San Francisco, CA 94104 

VERSANT VENTURE CAPITAL VI, L.P. 

One Sansome Street, Suite 3630 
 San Francisco, CA 94104 

MPM BIOVENTURES 2014, L.P. 
 450 Kendall
St. 
 Cambridge, MA, 02142 
 MPM BIOVENTURES
2014 (B), L.P. 
 450 Kendall St. 
 Cambridge, MA, 02142

 MPM ASSET MANAGEMENT INVESTORS BV2014 LLC 

450 Kendall St. 
 Cambridge, MA, 02142 

UBS ONCOLOGY IMPACT FUND, L.P. 

450 Kendall St. 
 Cambridge, MA, 02142 

BDC CAPITAL INC. 
 c/o
Business Development Bank of Canada 
 5 Place Ville Marie 

Bureau 400 
 Montréal, QC H3B 5E7 

  
 53 

 FONDS DE SOLIDARITÉ DES
TRAVAILLEURS DU QUÉBEC (F.T.Q.) 
 545, boul. Crémazie Est 

Bureau 200 
 Montréal, QC H2M 2W4 

COWEN HEALTHCARE INVESTMENTS II L.P. 

599 Lexington Avenue, 19th Floor 
 New York, NY 10022 

CHI EF II LP 
 599 Lexington Avenue, 19th Floor 

New York, NY 10022 
 VERSANT
VANTAGE I, L.P. 
 One Sansome Street, Suite 3630 

San Francisco, CA 94104 

ORBIMED PRIVATE INVESTMENTS VII, LP 

c/o OrbiMed Advisors LLC 
 601 Lexington Avenue, 54th Floor 

New York, NY 10022 
 REDMILE
BIOPHARMA INVESTMENTS II, L.P. 
 c/o Redmile Group, LLC 

One Letterman Drive, Suite D3-300 

The Presidio, San Francisco, CA 94129 

BIOTECHNOLOGY VALUE FUND, LP 

44 Montgomery Street, 40th Floor 
 San Francisco, CA 94104 

BIOTECHNOLOGY VALUE FUND II, LP 

44 Montgomery Street, 40th Floor 
 San Francisco, CA 94104 

BIOTECHNOLOGY VALUE TRADING FUND OS, LP 

PO Box 309 Ugland House 
 Grand Cayman, KY1- 1104, Cayman Islands 
 MSI BVF SPV LLC 

c/o Magnitude Capital 
 200 Park Avenue, 56th Floor 
 New York, NY 10166 

  
 54 

 LOGOS OPPORTUNITIES FUND I, L.P. 

345 California Street, Suite 600 
 San Francisco, CA 94104 

  
 55 

 SCHEDULE C 

COUNTERPART SIGNATURE PAGE TO THE AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT 

The undersigned hereby acknowledges receipt of a copy of the amended and restated registration rights agreement dated as of September 3, 2019 (the
“Agreement”) between Repare Therapeutics Inc. and certain other parties and, by executing this Counterpart Signature Page, the undersigned agrees to become a party to the Agreement, thereby having all of the rights and benefits, and
being subject to all of the obligations, of an Investor (as such term is defined in the Agreement) contained in the Agreement as if the undersigned were an original signatory. 

DATED this _____ day of ____________ __, 2019. 
 If an
individual: 
  

			
	 Signature:
	 	
         

	 Name (please Print):
	 	

 If a corporation, limited partnership or other legal entity: 

 

			
	 Name of Subscriber:
	 	
 

					
			
	         
	 	 By:
	 	  

		 		 	 Name:    

		 		 	 Title:

 Accepted as of ____________ __, ________. 

 

			
	REPARE THERAPEUTICS INC.
		
	Per:	 	          

		 	Name:
		 	Title:

  
 56EX-4.3

 Exhibit 4.3 

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN QUALIFIED FOR DISTRIBUTION UNDER APPLICABLE CANADIAN SECURITIES LEGISLATION OR
REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”). NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY BE SOLD, DISTRIBUTED, OFFERED FOR SALE, ASSIGNED, PLEDGED OR
OTHERWISE TRANSFERRED UNLESS (A) IN CANADA, A RECEIPT FOR A FINAL PROSPECTUS QUALIFYING SUCH TRANSACTION HAS BEEN OBTAINED UNDER APPLICABLE CANADIAN SECURITIES LEGISLATION OR A PROSPECTUS EXEMPTION QUALIFYING SUCH TRANSACTION IS AVAILABLE UNDER
APPLICABLE CANADIAN SECURITIES LEGISLATION, OR (B) IN THE UNITED STATES, THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER THE U.S. SECURITIES ACT COVERING SUCH TRANSACTION, OR SUCH TRANSACTION IS EXEMPT FROM REGISTRATION UNDER THE U.S.
SECURITIES ACT. 
 THE COMPANY (AS DEFINED BELOW) IS NOT A “REPORTING ISSUER” AS SUCH TERM IS DEFINED UNDER APPLICABLE CANADIAN SECURITIES LAWS.
THERE IS NO ASSURANCE THAT THE COMPANY WILL BECOME A “REPORTING ISSUER”. THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF WILL BE SUBJECT TO RESALE RESTRICTIONS UNDER APPLICABLE CANADIAN SECURITIES LAWS. UNLESS PERMITTED UNDER
APPLICABLE CANADIAN SECURITIES LEGISLATION, THE HOLDER OF THIS WARRANT AND ANY SECURITIES ISSUABLE UPON EXERCISE HEREOF MUST NOT TRADE THE WARRANT OR SUCH SECURITIES BEFORE THE DATE THAT IS 4 MONTHS AND A DAY AFTER THE LATER OF (A) THE
EFFECTIVE DATE (AS DEFINED BELOW) AND (B) THE DATE THE COMPANY BECAME A REPORTING ISSUER IN ANY PROVINCE OR TERRITORY OF CANADA. 
 IN ADDITION, NO
SALE, DISTRIBUTION, OFFER, ASSIGNMENT, PLEDGE, HYPOTHECATION OR OTHER TRANSFER OF THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY BE MADE EXCEPT IN ACCORDANCE WITH THE TERMS AND CONDITIONS HEREIN, APPLICABLE SECURITIES LAWS AND, AS
APPLICABLE, THE SECOND AMENDED AND RESTATED UNANIMOUS SHAREHOLDER AGREEMENT DATED SEPTEMBER 3, 2019 BETWEEN THE COMPANY AND ITS SHAREHOLDERS, AS SAME MAY BE AMENDED OR RESTATED FROM TIME TO TIME IN ACCORDANCE WITH ITS TERMS. 

WARRANT AGREEMENT 
 To
securities in the capital of 
 REPARE THERAPEUTICS INC. 

Dated as of May 26, 2020 (the “Effective Date“) 

WHEREAS, Repare Therapeutics Inc., a corporation incorporated pursuant to the Canada Business Corporations Act (the “Company”) desires
to grant to BMS Strategic Portfolio Investments Holdings, Inc., a Delaware corporation (the “Warrantholder”), and the Warrantholder wishes to subscribe for, in consideration for a subscription price of US$15,000,000, the right to
acquire common shares in the capital of the Company or preferred shares in the capital of the Company, as the case may be, pursuant to and in accordance with the terms of this Warrant Agreement (this “Agreement” or
“Warrant”); 
 NOW, THEREFORE, in consideration of the subscription price of US$15,000,000, the receipt of which is hereby acknowledged by
the Company, and in consideration of the mutual covenants and agreements contained herein, the Company and the Warrantholder agree as follows: 
  

	SECTION 1	 DEFINED TERMS 

In this Agreement, 
 “Affiliates”
means, with respect to any Person, any other Person that directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with the specified Person. As used

  
 1 

 
in this definition, “control”, “controlled by” and “under common control with” means possession, directly or indirectly, of power to direct or cause the direction of
management or policies of such Person (whether through ownership of securities or other partnership or ownership interests, as trustee, personal representative or executive or by contract, credit agreement or otherwise), provided that in any event,
any Person which owns directly, indirectly or beneficially 50% or more of the securities having voting power for the election of directors or other governing body of a corporation or 50% or more of the partnership interests or other ownership
interests of any other Person will be deemed to control such Person; 
 “Agreement” has the meaning ascribed thereto in the
recitals; 
 “Articles of Incorporation” means the articles of incorporation of the Company, as amended and restated from
time to time; 
 “A&R Registration Rights Agreement” has the meaning ascribed thereto in Section 7.7; 

“Cap Price” has the meaning ascribed thereto in Section 3.2(i); 

“Change of Control” means any sale, exchange, merger, amalgamation, consolidation, reorganization, arrangement, business
combination, conveyance or similar transaction or other disposition of securities of the Company (other than through the issuance of equity securities by the Company as part of a financing transaction), in a transaction or series of related
transactions after giving effect to which more than 50% of the voting power of shareholders of the Company is held by shareholders of the Company who were not voting shareholders (or Affiliates thereof) immediately prior to the first of such
transactions; 
 “Class C Preferred Shares” means class C convertible preferred shares in the capital of the Company which,
once created upon the filing by the Company of amended and restated Articles of Incorporation prior to their issuance to the Warrantholder in accordance with the terms hereof, will have attached thereto the rights, privileges, restrictions and
conditions as described in the form of amended and restated Articles of Incorporation attached as Schedule A hereto; 
 “Common
Shares” means the common shares in the capital of the Company; 
 “Company” means Repare Therapeutics Inc., a
corporation incorporated pursuant to the Canada Business Corporations Act; 
 “Effective Date” has the meaning
ascribed thereto in the recitals; 
 “Financing Shares” has the meaning ascribed thereto in Section 2.6; 

“Fully Diluted Shares” has the meaning ascribed thereto in Section 3.2(ii); 

“IPO” means the sale of the Common Shares in the United States to the public through a firm commitment underwritten initial
public offering pursuant to a registration statement on Form S-1 filed under the U.S. Securities Act; 

“Issuance Deadline” has the meaning ascribed thereto in Section 2.4; 

“Liquidation Event” means the liquidation, dissolution or winding-up of the affairs of
the Company or, unless waived by the Requisite Majority Preferred Shareholders in accordance with the Articles of Incorporation, a Sale of the Company; 

“Person” means any individual, partnership, limited partnership, joint venture, syndicate, sole proprietorship, company or
corporation with or without share capital, unincorporated association, trust, trustee, executor, administrator or other legal personal representative; 

  
 2 

 “Preferred Shares” means the Class A convertible preferred shares in
the capital of the Company, the Class B convertible preferred shares in the capital of the Company, and, if Class C Preferred Shares are issued and outstanding at the relevant time, the Class C Preferred Shares; 

“Qualified Financing” means an equity financing transaction involving the sale and issuance of the Company’s preferred
shares in the capital of the Company that results in gross proceeds to the Company of not less than US$50,000,000 (for clarity, before deduction of transaction expenses) and where at least 50% of the number of such preferred shares are issued to
investors who are not (and whose Affiliates are not) shareholders of the Company prior to such transaction, provided, however, that any securities issued in connection with an acquisition of any business or assets, mergers, licenses, strategic
partnerships or corporate partnering or collaboration agreements or similar transactions shall be excluded from the calculation when determining whether the foregoing 50% threshold has been met. 

“Requisite Majority Preferred Shareholders” means the shareholders of record of the Company holding at least 70% of the issued
and outstanding Preferred Shares at any relevant time; 
 “Sale of the Company” means any Change of Control or a sale,
lease, exclusive license, transfer or other disposition of all or substantially all of the assets or intellectual property of the Company and its respective subsidiaries, taken as a whole (except to an Affiliate); 

“Shareholders” means the shareholders of record of the Company at any relevant time; 

“Shareholders Agreement” means the second amended and restated unanimous shareholders agreement of the Company dated
September 3, 2019 entered into among the Company and its Shareholders; 
 “U.S. Securities Act” means the United States
Securities Act of 1933, as amended; 
 “Warrant Exercise Trigger Event” has the meaning ascribed thereto in
Section 2.1; 
 “Warrant” has the meaning ascribed thereto in the recitals; 

“Warrantholder” has the meaning ascribed thereto in the recitals; and 

“Warrant Shares” means (i) if this Warrant is exercised pursuant to Section 2.1(i), Common Shares, (ii) if this
Warrant is exercised pursuant to Sections 2.6, the Financing Shares, and (iii) if this Warrant is exercised in connection with any Warrant Exercise Trigger Event other than those set forth in Section 2.1(i), Class C Preferred
Shares. 
  

	SECTION 2	 AUTOMATIC AND OPTIONAL EXERCISE 

2.1 Subject to the remaining provisions of this Section 2, this Warrant shall be automatically exercised (which exercise will be in whole and not in part)
upon the earliest of: 
  

	 	(i)	 immediately prior to, but subject to, the closing of an IPO; 

 

	 	(ii)	 December 31, 2020; 

 

	 	(iii)	 the day on which the Company delivers to the Warrantholder a written notice to the effect that the Company is
no longer pursuing an IPO; and 

  

	 	(iv)	 immediately prior to the consummation of a Liquidation Event. 

(each such event described in subclauses (i) through (iv) above, a “Warrant Exercise Trigger Event”). 

  
 3 

 2.2 In the case of a Warrant Exercise Trigger Event referred to in subclause (i) or (iv) above,
the Company shall give the Warrantholder reasonable prior written notice of the anticipated closing or completion of such Warrant Exercise Trigger Event, as is reasonably practicable under the circumstances of such transaction but no later than five
(5) days prior to the completion of such Warrant Trigger Event. 
 2.3 Subject to the remaining provisions of this Section 2, this Warrant shall
be automatically exercised (which exercise will be in whole and not in part) upon the occurrence of a Warrant Exercise Trigger Event, without the Warrantholder being required to deliver to the Company a notice of exercise and without the need of the
Warrantholder to pay any exercise price or further amount. For the avoidance of doubt, this Warrant may only be exercised upon a Warrant Exercise Trigger Event, and is not subject to any discretionary, voluntary or forced exercise by the Warrant
Holder or the Company under any other circumstance. In the case of a Warrant Exercise Trigger Event referred to in subclause (ii) or (iii) above, the Company and the Warrantholder shall execute and deliver a subscription or stock purchase
agreement pursuant to which the Company will issue the Warrant Shares to the Warrantholder and, in connection therewith, will provide representations and warranties for the benefit of the Warrantholder substantially similar in scope to those
representations and warranties set forth in that certain Class B Share Subscription Agreement, dated August 27, 2019, by and among the Company and the purchasers of Preferred Shares party thereto, provided that such representations and
warranties shall be updated by the Company to reflect the changes to the Company’s capitalization, business and other matters since August 27, 2019. 

2.4 Promptly upon the occurrence of a Warrant Exercise Trigger Event, and in no event later than twelve (12) days thereafter (the “Issuance
Deadline”), the Company shall, unless otherwise provided for herein or as may be mutually agreed to between the Company and the Warrantholder, take such actions as are required to issue the Warrant Shares, including obtaining the requisite
approval of the Company’s shareholders to file, and filing, amended and restated Articles of Incorporation in the form attached as Schedule A hereto, and immediately thereafter, shall either (i) issue to the Warrantholder a certificate for
the number of Warrant Shares acquired or (ii) cause the Company’s share register to reflect the issuance through book-entry or otherwise of the Warrant Shares in the name of the Warrantholder. The Warrantholder will for all purposes be
deemed to have become the holder of record of the Warrant Shares at the time and on the date on which the Warrant Exercise Trigger Event occurred, irrespective of the date of delivery (if any) of the certificate representing the Warrant Shares, and
the Warrantholder shall be treated for all purposes as the holder of the Warrant Shares as of such Warrant Exercise Trigger Event. If the Company shall fail to fully perform all of its obligations under this Section 2.4 on or before the
Issuance Deadline, interest shall accrue at a rate of 5% per annum on the Warrant subscription price of US$15,000,000 commencing on the Issuance Deadline, which interest shall be paid quarterly in cash to the Warrantholder, with any accrued but
unpaid interest converting into Warrant Shares at the same price per Warrant Share at which the Warrant subscription price of US$15,000,000 is converted concurrently with the Company’s issuance of the Warrant Shares to the Warrantholder.

2.5 Notwithstanding anything to the contrary set forth in this Section 2, if this Warrant is automatically exercised in connection with the completion of
a Liquidation Event, the Warrant Holder shall receive, in lieu of the Class C Preferred Shares it would be entitled to upon exercise of this Warrant, an amount in cash equal to the amount in cash or other consideration that would have been
payable to the Warrantholder in respect of such Class C Preferred Shares (including any contingent cash payments payable following the closing of such Liquidation Event) pursuant to the rights, privileges, restrictions and conditions attached
to the Class C Preferred Shares as described in the form of amended and restated Articles of Incorporation attached as Schedule A hereto as if the Warrantholder was the holder of the Class C Preferred Shares immediately prior to the
completion of the Liquidation Event and as if such Liquidation Event were a “Liquidation Event” under such amended and restated Articles of Incorporation; provided, however, that for greater clarity, the Warrantholder shall be delivered
the cash or other consideration that would have been payable to the Warrantholder in respect of Common Shares in connection with the Liquidation Event, if (i) the Warrantholder would obtain a higher consideration value if it had voluntarily
exercised its Class C Conversion Privilege than it otherwise would be entitled to if it did not convert its Class C Preferred Shares, or (ii) there is a “Forced Conversion Event” as defined in the Articles of Incorporation
prior to such Liquidation Event. 
 2.6 Notwithstanding anything to the contrary set forth in this Section 2, if prior to the occurrence of a Warrant
Exercise Trigger Event, the Company contemplates completing a Qualified Financing, (i) the Company shall give the Warrantholder reasonable prior written notice of the anticipated closing of such Qualified Financing, (ii) the Warrantholder
may elect, by delivery of written notice to the Company within five (5) days following the Warrantholder’s receipt of such notice, to exercise this Warrant for a number of shares of the same class and series of

  
 4 

 
preferred shares issued by the Company to investors participating in such Qualified Financing (the “Financing Shares”) equal to the quotient of the Warrant subscription price of
US$15,000,000 divided by the Cap Price (as defined below), and (iii) in connection with such exercise, the Warrantholder shall become party to all agreements relating to the purchase and sale of the Financing Shares, including a subscription or
stock purchase agreement as well as any other stockholder agreements as are executed and delivered by all other investors participating in such Qualified Financing, and will receive the benefit of any representations, warranties and covenants of the
Company to the same extent as all other investors participating in such Qualified Financing. 
  

	SECTION 3	 NUMBER AND CLASS OF WARRANT SHARES 

3.1 For the consideration of the subscription price of US$15,000,000, the receipt of which is hereby acknowledged by the Company, subject to Section 2.6,
upon the occurrence of a Warrant Exercise Trigger Event, this Warrant shall be automatically exercised for the number and class of Warrant Shares set forth below: 
  

	 	(i)	 if the exercise of the Warrant is pursuant to Section 2.1(i), the Warrantholder shall be entitled to an
aggregate number of fully paid and non-assessable Common Shares equal to the quotient derived by dividing (A) the Warrant subscription price of US$15,000,000 by (B) the initial “Price to
Public” per Common Share specified in the final prospectus with respect to the IPO; or 

  

	 	(ii)	 if the exercise of the Warrant is in connection with any Warrant Exercise Trigger Event other than that set
forth in Section 2.1(i), then subject to Section 2.5, the Warrantholder shall be entitled to an aggregate number of fully paid and non-assessable Class C Preferred Shares equal to the quotient
derived by dividing (A) the Warrant subscription price of US$15,000,000 by (B) the Cap Price (as defined below). 

 3.2 For
purposes of this Warrant: 
  

	 	(i)	 “Cap Price” means the price per share equal to the quotient of (A) US$375,000,000 divided
by (B) the number of Fully Diluted Shares as of immediately prior to the exercise of this Warrant. 

  

	 	(ii)	 “Fully Diluted Shares” means, at any given time, the aggregate sum of (A) the number of
Common Share then outstanding, plus (B) the number of Common Shares issuable upon the exercise or conversion of any options (whether vested or unvested), warrants (whether vested or unvested), preferred shares or other convertible
securities of the Company (other than this Warrant) then outstanding, plus (C) the number of Common Shares then reserved for future issuance under the Company’s equity incentive plans or similar arrangements, provided that the
number of Fully Diluted Shares will take into account the impact of any in-the-money convertible security or share award under the Company’s equity incentive plans
or similar arrangements, as calculated by the treasury stock method. 

 3.3 If this Warrant is exercised pursuant to Section 2.1(i),
the parties hereto will thereafter work collaboratively and in good faith on a commercially reasonable basis in order to put into place an effective limit on the Warrantholder’s voting rights as they pertain to the Warrant Shares and any other
shares in the capital of the Company issued by the Company to the Warrantholder and its Affiliates (excluding, for greater certainty, any shares purchased by Warrantholder and/or its Affiliates on the open market following the consummation of the
IPO), such that the aggregate number of votes that may be exercised by the Warrantholder and its Affiliates in respect of such shares in the capital of the Company at any time shall not exceed 19.99% of the aggregate voting power of all outstanding
shares in the capital of the Company, the whole subject to and in accordance with applicable securities laws and stock exchange rules. 
  

	SECTION 4	 NO FRACTIONAL SHARES 

No fractional Warrant Shares shall be issued upon the exercise of this Warrant, and the number of Warrant Shares issued upon the automatic exercise of the
Warrant shall be rounded down to the nearest whole Warrant Share. 

  
 5 

	SECTION 5	 NO RIGHTS AS SHAREHOLDER 

This Agreement does not entitle, and nothing in this Warrant shall be construed as conferring upon, the Warrantholder or any other Person the right to vote or
consent or to receive notice as a shareholder in respect of meetings of shareholders for any matters or any rights whatsoever as a shareholder of the Company prior to the time that this Warrant is automatically exercised as described above. 

 

	SECTION 6	 ADJUSTMENT OF RIGHTS 

6.1 Adjustment and Antidilution Rights. Adjustment rights applicable to the Class C Preferred Shares that may be acquired hereunder
are set forth in sections 4.3.5 (Adjustment for Stock Splits and Combinations), 4.3.6 (Adjustment for Certain Dividends and Distributions), 4.3.7 (Adjustment for Reclassification, Exchange, or Substitution) and 4.3.8
(Adjustment for Merger or Reorganization, etc.) of the form of amended and restated Articles of Incorporation attached as Schedule A hereto and shall be applicable with respect to the Class C Preferred Shares underlying this Warrant
as if such amended and restated Articles of Incorporation were in force as of the Effective Date and as if the Warrantholder held the Class C Preferred Shares underlying this Warrant as of the Effective Date. In addition, antidilution rights
applicable to the Class C Preferred Shares that may be acquired hereunder are as set forth in section 4.3.9 of the form of amended and restated Articles of Incorporation attached as Schedule A hereto and shall be applicable with respect to
the Class C Preferred Shares underlying this Warrant as if such amended and restated Articles of Incorporation were in force as of the Effective Date and as if the Warrantholder held the Class C Preferred Shares underlying this Warrant as
of the Effective Date. 
 6.2 Certificate of Adjustment. From an after the Effective Date until the occurrence of a Warrant Exercise Trigger Event,
in each case of an adjustment or readjustment is required to be made pursuant to Section 6.1, the Company shall compute such adjustment or readjustment in accordance with the provisions hereof and prepare a certificate showing such adjustment
or readjustment, and shall deliver to the Warrantholder at the address set forth in Section 10.6. The certificate shall set forth such adjustment or readjustment showing in reasonable detail the facts upon which such adjustment or readjustment
is based 
  

	SECTION 7	 REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY 

The Company represents and warrants to the Warrantholder and acknowledges that the Warrantholder is relying upon the following representations and warranties
in connection with the entering into of this Agreement: 
 7.1 Due Authority. The execution and delivery by the Company of this Agreement and the
performance of all obligations of the Company hereunder, including the issuance to Warrantholder of the Common Shares or the Class C Preferred Shares that may be issued upon exercise of this Warrant, as the case may be, have been duly
authorized by all necessary corporate action on the part of the Company; provided, however, that the creation of the Class C Preferred Shares remains subject to the formalities outlined in Section 7.6 below. This Agreement: (i) does
not violate the Articles of Incorporation, the Company’s current bylaws or the Shareholders Agreement; (ii) does not contravene any law or governmental, regulation or order applicable to it; and (iii) does not contravene any provision
of, or constitute a default under, any indenture, mortgage, contract or other instrument to which it is a party or by which it is bound. This Agreement constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with
its terms. The Company has made available to the Warrantholder true, correct and complete copies of its Articles of Incorporation, bylaws and Shareholders Agreement. 

7.2 Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state,
provincial, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Agreement, except, if applicable for the filing of notices with the SEC
pursuant to Regulation D under the U.S. Securities Act and any filing required by applicable U.S. state securities law, which filings will be effective by the time required thereby. 

7.3 Authorized Share Capital. The authorized share capital of the Company consists of (A) an unlimited number of Common Shares, of which
10,657,916 Common Shares are issued and outstanding, (B) an unlimited number of Class A Preferred Shares, of which 67,228,395 Class A Preferred Shares are issued and outstanding and are convertible

  
 6 

 
into Common Shares as set forth in the Articles of Incorporation, and (C) an unlimited number of Class B Preferred Shares, of which 63,458,580 Class B Preferred Shares are issued
and outstanding and are convertible into Common Shares as set forth in the Articles of Incorporation. Other than pursuant to the Company’s incentive stock option plan, there are no other options, warrants, conversion privileges or other rights
presently outstanding to purchase or otherwise acquire any authorized but unissued shares in the capital of the Company or other securities of the Company. 

7.4 Valid Issuance. The Common Shares or the Class C Preferred Shares that may be issued upon exercise of this Warrant, and, if applicable, the
issuance of the Common Shares upon conversion of the Series C Preferred Shares underlying this Warrant, shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and will be free
of any liens and encumbrances of any nature whatsoever; provided, that the Warrant Shares issuable pursuant to this Agreement may be subject to restrictions on transfer under Canadian securities laws or under U.S. state and/or federal securities
laws. 
 7.5 Exempt Transaction. Subject to the accuracy of the Warrantholder’s representations in Section 8, as of the date of this
Agreement and as of the date of exercise of this Warrant, the issuance of the Common Shares or the Class C Preferred Shares that may be issued hereunder upon exercise of this Warrant, and, if applicable, the issuance of the Common Shares upon
conversion of the Series C Preferred Shares underlying this Warrant, will each constitute a transaction exempt from (i) the registration requirements of Section 5 of the U.S. Securities Act, in reliance upon Section 4(a)(2)
thereof, (ii) the qualification requirements of the applicable U.S. state securities laws, and (iii) the requirement to file a prospectus with any securities regulatory authority in any province or territory of Canada. 

7.6 Shareholder Approval. 
  

	 	(i)	 Requisite Majority Preferred Shareholders. The Requisite Majority Preferred Shareholders:

 (A) have deemed that this Warrant, the Common Shares or the Class C Preferred Shares that may be issued upon
exercise of this Warrant and the Common Shares underlying the Class C Preferred Shares that may be issued hereunder, each shall be Excluded Securities as defined in the Articles of Incorporation and, therefore, this Warrant and the securities
to be issued hereunder are not subject to the pre-emptive rights in the Shareholders Agreement; 

(B) have consented to the filing by the Company of amended and restated Articles of Incorporation in the form attached as Schedule A hereto in
order to create and authorize, if and when required in accordance with the terms of this Warrant, the Class C Preferred Shares; 
 (C)
have consented to the amendments to (i) the Shareholders Agreement reflected in the form of the third amended and restated unanimous shareholders agreement of the Company attached as Schedule B hereto and (ii) the A&R Registration
Rights Agreement reflected in the form of the second amended and restated registration rights agreement of the Company attached as Schedule C hereto; and 

(D) have undertaken to take all steps necessary and to execute such other documents and agreements to give effect to the matters set out above
and the issuance of the Common Shares or the Class C Preferred Shares that may be issued upon exercise of this Warrant, including without limitation (i) to execute a written resolution of the Company’s shareholders approving the
filing by the Company of amended and restated Articles of Incorporation in the form attached as Schedule A hereto in order to create and authorize, if and when required in accordance with the terms of this Warrant, the Class C Preferred Shares;
and (ii) to the extent necessary, to attend and vote at a meeting of the Company’s shareholders in favour of the approval thereof. 
  

	 	(ii)	 Meeting or Resolution in lieu of Meeting. The Company shall, as soon as is reasonably practicable, and
in any event on or before the earlier to occur of a Warrant Exercise Trigger Event or July 31, 2020: 

  
 7 

 (A) submit to its Shareholders a written resolution, for execution in lieu of a meeting,
authorizing the Company to file amended and restated Articles of Incorporation in the form attached as Schedule A hereto in order to create and authorize, if and when required in accordance with the terms of this Warrant, the Class C
Preferred Shares; and 
 (B) if the Company is not able to obtain the written resolution in lieu of a meeting in accordance with
applicable corporate law, conduct a meeting of all of its Shareholders in accordance with the Articles of Incorporation, the Company’s by-laws and the Shareholders Agreement for the approval of a
resolution authorizing the Company to file amended and restated Articles of Incorporation in the form attached as Schedule A hereto. 
  

	 	(iii)	 Form of Amended and Restated Shareholders Agreement and Registration Rights Agreement. As of the date
hereof, the Requisite Majority Preferred Shareholders have consented to the amendments to (A) the Shareholders Agreement reflected in the form of the third amended and restated unanimous shareholders agreement of the Company attached as
Schedule B hereto, and (B) the A&R Registration Rights Agreement (as defined below) reflected in the form of the second amended and restated registration rights agreement of the Company attached as Schedule C hereto. 

7.7 Registration Rights. The Company agrees that the Warrantholder shall have the registration rights and be subject to the terms pursuant to and as
set forth in the amended and restated registration rights agreement dated September 3, 2019 among the Company and the Investors (as such term is defined therein) (the “A&R Registration Rights Agreement”) with respect to the
Common Shares or the Class C Preferred Shares that may be issued upon exercise of this Warrant once such Warrant Shares are so issued, provided that the Warrantholder has executed the second amended and restated registration rights agreement
attached as Schedule C hereto. 
  

	SECTION 8	 REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER 

The Warrantholder represents and warrants to the Company and acknowledges that the Company is relying upon the following representations and warranties in
connection with the entering into of this Agreement: 
 8.1 Investment Purpose. This Warrant and the securities to be acquired upon exercise of this
Warrant by the Warrantholder are being acquired for investment purposes for the Warrantholder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of applicable securities laws,
except as may be permitted under applicable securities laws. The Warrantholder also represents that it has not been formed for the specific purpose of acquiring this Warrant or the Warrant Shares. 

8.2 Private Issue. The Warrantholder understands (i) that the Warrant Shares issuable upon exercise of this Agreement are not qualified pursuant
to a prospectus filed with any securities regulatory authority in Canada or registered under the U.S. Securities Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Agreement will be exempt
from the registration and qualifications requirements thereof and from the requirement to file a prospectus under Canadian securities laws, and (ii) that the Company’s reliance on such exemption is predicated on the representations set
forth in this Section 8. 
 8.3 Financial Risk. The Warrantholder understands that the purchase of this Warrant and its underlying securities
involves substantial risk. The Warrantholder has experience as an investor in securities of companies in the development stage and acknowledges that it can bear the economic risk of such Warrantholder’s investment in this Warrant and its
underlying securities and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and has a preexisting business
relationship with the Company of a nature and duration that enables the Warrantholder to be aware of the character, business acumen and financial circumstances of the Company. 

8.4 Risk of No Registration. The Warrantholder understands that if (i) the Company does not register with the SEC pursuant to Section 12 of
the Securities Exchange Act of 1934 (the “1934 Act”), (ii) the Company does not file reports pursuant to Section 15(d) of the 1934 Act, (iii) a registration statement covering the securities under the Act is not in effect
or (iv) the Company has not been a reporting issuer in any province or territory of Canada for at least four 

  
 8 

 
months and a day, in each case when it desires to sell the Warrant Shares, it may be required to hold such securities for an indefinite period. The Warrantholder also understands that any sale of
Warrant Shares issued or issuable hereunder which might be made by it in reliance upon a prospectus exemption contained in Regulation 45-106 respecting Prospectus and Registration Exemptions (Quebec) or under
Rule 144 under the U.S. Securities Act may be made only in accordance with the terms and conditions of that that regulation or rule. The Warrantholder understands that Warrant Shares issued hereunder will have a legend describing applicable transfer
restrictions. 
 8.5 No Public Market. The Warrantholder acknowledges that no public market presently exists for any securities of the Company, and
there can be no assurance that any such market will be created. 
 8.6 No General Solicitation. The Warrantholder is not acquiring this Warrant as a
result of any “general solicitation” or “general advertising” within the meaning of SEC Rule 502 of Regulation D, as presently in effect. 

8.7 Accredited Investor and Permitted Client. The Warrantholder is (i) an “accredited investor” within the meaning of the Securities
Act (Quebec) and Regulation 45-106 respecting Prospectus and Registration Exemptions (Quebec) and of Rule 501 of Regulation D under the U.S. Securities Act, as presently in effect, and (ii) a
“permitted client” within the meaning of National Instrument 31-103—Registration Requirements, Exemptions and Ongoing Registrant Obligations, and is purchasing the Warrant pursuant to an
exemption from the prospectus requirements of applicable securities laws. 
 8.8 Lock-Up. The Warrantholder
hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the Company’s IPO and ending on the date specified by the Company and
the managing underwriter (such period not to exceed 180 days): (a) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or
otherwise transfer or dispose of, directly or indirectly, any Warrant Shares held immediately prior to the effectiveness of the registration statement for the IPO; or (b) enter into any swap or other arrangement that transfers to another, in
whole or in part, any of the economic consequences of ownership of the Warrant Shares, whether any such transaction described in clause (a) or (b) above is to be settled by delivery of Shares (as such term is defined in the Shareholders
Agreement) or other securities, in cash or otherwise. The Warrantholder further agrees to execute such agreements as may be reasonably requested by the underwriters in the IPO that are consistent with this Section 8.8 or that are necessary to
give further effect thereto. For greater clarity, this Section 8.8 shall apply even if the Company’s IPO occurs after December 31, 2020. 
  

	SECTION 9	 TRANSFERS 

Except as contemplated herein, no sale, distribution, assignment, offer, pledge, hypothecation or other transfer of this Warrant may be made by the
Warrantholder without the prior written approval of the Company (such approval not be unreasonably withheld, conditioned or delayed); provided, that, this Warrant may be transferred by the Warrantholder, in whole (but not in part), to any Affiliate
of the Warrantholder (such Affiliate, for as long as it is an Affiliate of the Warrantholder, a “Permitted Transferee”) without the prior written approval of the Company. Subject to compliance to the reasonable satisfaction of the
Company with the conditions contained herein and applicable securities legislation, upon surrender of this Warrant properly endorsed or accompanied by written instructions of transfer attached as Schedule D hereto, the Company will issue a new
Warrant to the Permitted Transferee reflecting the transfer from the Warrantholder of this Warrant in substantially identical form to this Warrant. A Permitted Transferee shall remain an Affiliate of the Warrantholder for as long as it holds a
Warrant reflecting the right to acquire Warrant Shares. The terms and conditions of this Warrant will inure to the benefit of, and be binding on, the respective successors and permitted assigns of the Company and the Warrantholder, respectively.

  

	SECTION 10	 MISCELLANEOUS 

10.1 Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and
enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where Warrantholder will not have an
adequate remedy at law and where damages will not be readily ascertainable. The Company expressly agrees that it shall not oppose an application by the Warrantholder or any other Person entitled to the benefit of this Agreement requiring specific
performance of any or all provisions hereof or enjoining the Company from continuing to commit any such breach of this Agreement. 

  
 9 

 10.2 No Impairment of Rights. The Company will not, by amendment of the Articles of Incorporation or
through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be
necessary or appropriate in order to protect the rights of the Warrantholder against impairment. 
 10.3 Attorneys’ Fees. The prevailing party
in any action to enforce, construe, interpret or otherwise arising in relation to this Agreement, shall be entitled to an award of its reasonable attorneys’ fees and costs incurred as a result of the action and any appeals therefrom. 

10.4 Severability. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or unenforceable, the
remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties
underlying the invalid, illegal or unenforceable provision. 
 10.5 Notices. Except as otherwise provided herein, any notice, demand, request,
consent, approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing, shall be sent by personal delivery, courier
or electronic mail, and shall be addressed to the party to be notified as follows: 
  

	 	(i)	 If to Warrantholder: 

Bristol-Myers Squibb Company 
 430
E. 29th Street, 14th Floor 
 New York, NY 10016 

Attention: General Counsel 
 with
a copy to (which shall not constitute notice): 
 Bristol-Myers Squibb Company 

Route 206 & Province Line Road 

Princeton, NJ 08543-4000 
 Attn:
Andrew Fedder, Esq. 
 and 

Covington & Burling LLP 

620 Eighth Avenue 
 New York, NY
10018-1405 
 Attn: Andrew Ment, Esq. 
  

	 	(ii)	 If to the Company: 

Repare Therapeutics Inc. 
 100-7210 Rue Frederick-Banting 
 Saint-Laurent, Québec H4S 2A1 

Attention: Kim Seth 

  
 10 

 with a copy to (which shall not constitute notice): 

Stikeman Elliott LLP 
 1155
René-Lévesque Blvd. West, #4100 
 Montreal, Québec H3B 3V2 

Attention: Sidney Horn / Robert Carelli / Jeremy Sculnick 

Any such notice, demand, request, consent, approval, declaration, service of process or other communication notice is deemed to be given and received
(i) if sent by personal delivery or courier, on the date of delivery if it is a business day and the delivery was made prior to 4:00 p.m. (local time in place of receipt) and otherwise on the next business day, or (ii) if sent by email,
upon receipt by sender of confirmation of receipt by the recipient, which confirmation shall be promptly by recipient if so requested by sender in the applicable notice or in a subsequent communication. A party may change its address for service
from time to time by providing a notice in accordance with the foregoing. Any subsequent notice, direction or other communication must be sent to the party at its changed address. Any element of a party’s address that is not specifically
changed in a notice will be assumed not to be changed. 
 10.6 Entire Agreement: Amendments. This Agreement constitutes the entire agreement and
understanding of the parties hereto in respect of the subject matter hereto and supersedes and replaces in their entirety any prior proposals, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter
hereof. None of the terms of this Agreement may be amended except by an instrument executed by each of the parties hereto. 
 10.7 Headings. The
various headings in this Agreement are inserted for convenience only and shall not affect the meaning or interpretation of this Agreement or any provisions hereof. 

10.8 No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity
or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any
provisions of this Agreement. 
 10.9 No Waiver. No omission or delay by the Warrantholder at any time to enforce any right or remedy reserved to it,
or to require performance of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of any such right or remedy to which the Warrantholder is entitled, nor shall it in any way affect the right of
the Warrantholder to enforce such provisions thereafter. 
 10.10 Survival. All agreements, representations and warranties contained in this
Agreement or in any document delivered pursuant hereto shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement. 

10.11 Governing Law. This Agreement will be governed by and construed in accordance with the laws of the Province of Quebec and the federal laws of
Canada applicable therein. 
 10.12 Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any
number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. 

[Remainder of Page Intentionally Left Blank] 

  
 11 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its officers thereunto
duly authorized as of the Effective Date. 
  

							
	 COMPANY:
	 	REPARE THERAPEUTICS INC.
			
	 	 	By:	 	 /s/ Lloyd Segal

	 	 	 	 	Name:	 	Lloyd Segal
	 	 	 	 	Title	 	President and CEO
		
	 WARRANTHOLDER:
	 	 BMS STRATEGIC PORTFOLIO

INVESTMENTS HOLDINGS, INC.

			
	 	 	By:	 	 /s/ Rupert Vessey

	 	 	 	 	Name:	 	Rupert Vessey
	 	 	 	 	Title:	 	EVP

  
 [Signature Page –
Warrant Agreement] 

 SCHEDULE A 

FORM OF AMENDED AND RESTATED ARTICLES OF INCORPORATION 

[See attached.] 

 SCHEDULE B 

FORM OF THIRD AMENDED AND RESTATED UNANIMOUS SHAREHOLDERS AGREEMENT 

[See attached.] 

 SCHEDULE C 

FORM OF SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT 

[See attached.] 

 SCHEDULE D 

TRANSFER NOTICE 
 (To transfer or assign
the foregoing Agreement execute this form and supply required information. Do not use this form in connection with the exercise of the foregoing Agreement.) 

FOR VALUE RECEIVED, the foregoing Agreement and all rights evidenced thereby are hereby transferred and assigned to 

 

					
	  

	
	(Please Print)
		
	whose address is	 	 
		
		 	 

  

					
	 Dated:

		
	Holders’s Signature	 	 
	
	Holder’s Address
			
		 	 	 	 

  

			
	Signature Guaranteed:	 	 

 NOTE; The signature to this Transfer Notice must correspond with the name as it appears on the face of the Agreement, without
alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Agreement.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]